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ABSTRACT
Drug transporters are membrane bound proteins, which are involved in
facilitating both uptake and efflux of xenobiotics, endogenous compounds and
their metabolites in various tissues such as liver, kidney, testis, and brain.
Alteration in drug transporters may cause imbalances in endogenous
compounds such as bile acids, hormones, and bilirubin.

Xenobiotic

metabolism is inefficient without drug transporters, and drug transporters are
recognized as vital mediators for moving polar compounds across
membranes.

ATP binding cassette (Abc) transporters are a kind of drug

transporters, which are ATP-dependent membrane bound proteins involved in
transport of wide variety of compounds. Multiple hepatic conditions can alter
drug transporter expression such as obesity, oxidative stress, cytokines, druginduced liver injury and environmental toxicants. Specifically, drug transporter
expression is known to alter during several metabolic conditions.

For

example, both genetically modified and diet-induced obesity models of rodents
displayed altered hepatic drug transporter expression.

Previous studies

shown not only during metabolic syndrome, but also exposure to xenobiotics
such as estradiol and polybrominated diphenyls (PBDs), which are endocrine
disrupting chemicals, alter drug transporter expression. The objective of this
study is to determine whether certain liver conditions, such as development of
fatty liver (i.e. steatosis) and developmental exposure to an environmental
endocrine disruptor (i.e. Bisphenol A) alter hepatic Abc drug transporter
expression in conjunction with nuclear receptor expression. This study also

aims to show, changes in hepatic Phase II and Abc drug transporter
expression during metabolic syndrome alters metabolism and disposition of
endocrine disruptor such as Bisphenol A (BPA) This research will provide
novel observation and mechanisms by which expression of drug transporters
will be affected and regulated.

To delineate these aspects whole thesis

research was divided into three specific sub studies:
In the first study, which is presented as Manuscript I shows changes
in hepatic Abc drug transporters, uptake transporters, Phase I enzyme
expression, and factor involved in regulation of hepatic Abc transporter
expression during development of obesity. This study also shows possible
physiological and transcription factors role in regulation of hepatic Abc
transporter expression during development of obesity. In this study, hepatic
gene expression and physiological factors were analyzed in both C57BL/6 and
ob/ob mice at different time points such as week-1, 3, 4 and 8 age to capture
physiological and gene expression changes that occur during development of
obesity. Correlation between physiological changes and gene expression was
performed using canonical correlations.

Significant correlations were

observed between physiological changes, hormones, and gene expression
changes during development of obesity. Correlation between metabolismrelated

hormones

and

hepatic

gene

expression

are

sex-dependent.

Correlation between physiological changes and gene expression indicated
metabolism-related hormones might have a role in regulation of hepatic genes
involved in drug metabolism and transport.

In second study, which is presented as Manuscript II shows changes
in hepatic Abc transporter expression with developmental exposure to
endocrine disruptor BPA and identifies mechanistic pathways by which BPA
exposure causes these effects. In this study, female mice are exposed to
either control or BPA or ethinyl estradiol (EE) or phytoestrogen enriched diet.
Studies were performed in male pups to analyze gene expression and
functional activities of respective genes. Developmental exposure to BPA and
EE downregulated hepatic drug transporters and Phase II enzyme expression
and activity that are involved in BPA metabolism and excretion, whereas
genistein co-administration reversed these changes. Changes observed with
developmental exposure of BPA were persistently observed even after
cessation of BPA exposure to male pups. Decrease in nuclear factors mRNA
expression

and

binding

activity

could

be

partially

responsible

for

downregulation of hepatic Phase II enzymes and drug transporter expression.
Further, increase in expression of histone deactylases (Hdac’s) upon BPA
exposure could be responsible for decreased transcription factor expression
and activity. Our data suggest that developmental BPA and EE exposure may
work via similar pathways, and greatly affect the expression of key hepatic
genes involved in BPA and hormone metabolism and clearance.
In third study, presented as Manuscript III shows changes in hepatic
drug metabolism gene expression observed during obesity alters BPA, an
endocrine disruptor disposition. This study aim to identify whether changes in
Phase II and drug transporter expression alters BPA disposition, as increase

in urinary total BPA levels and BPA exposure in humans are correlated to
occurrence of obesity. BPA (10 mg/kg, i.v.) was administered; parent and its
metabolites were analyzed in bile, plasma and urine sample of lean and obese
rats. Along with in vivo BPA disposition studies, hepatic glucuronidation and
sulfation enzymatic assays were performed to identify whether obesity altered
hepatic metabolic processes.

Changes in hepatic Phase II and III protein

expression in obese rats resulted in altered BPA metabolism and disposition.
In obese rats, BPA metabolites specifically BPA-glucuronide levels were
increased in urine and decreased in bile compared to lean rats. This altered
BPA metabolism and disposition during obesity suggests, in humans detailed
evaluation of urinary BPA levels such as ratio of metabolite to parent
compound, are needed to correlate BPA exposure to occurrence of obesity.
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PREFACE

This dissertation has been written in the manuscript format as directed by the
guidelines set by the Graduate School at the University of Rhode Island. Each
manuscript follows the format of the journal “Drug Metabolism and
Disposition”.
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INTRODUCTION
1. ATP Binding cassette (Abc) drug transporters:
The liver is the major organ for metabolism and clearance; it plays a
predominant role in determining the circulating systemic concentrations of
many endocrine hormones in the body.

In general, the metabolism of

endogenous chemicals and xenobiotics involves Phase-I, -II and -III (drug
transporters) proteins (Figure 1).

Drug transporters are membrane bound

proteins, which are involved in facilitating both uptake and efflux of
xenobiotics, endogenous compounds and their metabolites in various tissues
such as liver, kidney, testis, and brain. Alteration in drug transporters may
cause imbalances in endogenous compounds such as bile acids, hormones,
and bilirubin. Xenobiotic metabolism is inefficient without drug transporters,
and drug transporters are recognized as vital mediators for moving polar
compounds across membranes. ATP binding cassette (Abc) transporters are
a kind of drug transporters, which are ATP-dependent membrane-bound
proteins involved in transport of wide variety of compounds.

Multiple hepatic

conditions can alter drug transporter expression such as obesity, oxidative
stress, cytokines, drug-induced liver injury and environmental toxicants. Drug
transporters are involved in several critical liver functions such as absorption
and excretion, which determines the distribution and hepatic concentrations of
endogenous compounds in the body. Changes in drug transporter expression,
especially ABC transporters, can cause imbalances in homeostasis of
endogenous compounds in body, which may lead to several pathological
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conditions, such as cholestasis, hyperbilirubinemia, drug-induced liver injury
(Faber et al., 2003; Geier et al., 2003; Aleksunes et al., 2008; Lecureux et al.,
2009). Impairment of drug transporters causes several pathological conditions
such as cholestasis and hyperbilirubinemia.

Mice lacking certain drug

transporters, such as Abcc4, are more susceptible for liver injury during certain
pathological conditions, such as cholestasis. ABC transporters have seven
subfamilies from A to G such as ABCA, ABCB, ABCC, ABCD, ABCE, ABCF
and ABCG (Dean et al., 2001). ABC transporters are primarily involved in
efflux of endogenous and exogenous compounds.

Figure 1 Depiction xenobiotic and endogenous compounds metabolism
in liver.
In liver, ABC drug transporters are important in maintaining the bile acid pool,
fatty acids, and cholesterol transport and efflux of xenobiotic metabolites.
Drug transporters in liver are regulated by several nuclear receptors and
transcription factors such as nuclear factor-E2- related factor 2 (Nrf2), aryl
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hydrocarbon receptor (Ahr), constitutive androstane receptor (Car), estrogen
receptor (Er), and Peroxisome proliferator-activated receptor alpha (Ppar-α)
(Faber et al., 2003; Geier et al., 2003; Maher et al., 2005a). Activation of
nuclear hormones via pharmacological means or genetic manipulation often
upregulates drug Abcc transporter expression in liver (Faber et al., 2003;
Maher et al., 2005a).
For

example,

microsomal

enzyme

inducers,

such

as

[2,3,7,8-

tetrachlorodibenzo-p-dioxin (TCDD), polychlorinated biphenyl 126 (PCB126),
and

beta-naphthoflavone],

1,4-bis[2-(3,5-dichloropyridyloxy)]benzene

(TCPOBOP) increased Abcc2 expression in mouse liver (Maher et al., 2005a).
Certain exposures can down-regulate Abcc transporter expression in liver,
such as lipopolysaccharide (LPS) administration. Studies mentioned above
are adulthood exposure studies, only very few studies describe whether
transporters and hepatic clearance mechanisms are regulated by early in life
exposure that can contribute to epigenetic mechanisms.
Drug transporters and Phase-II enzyme expression in liver differs from
neonates to adults in rodent and humans (Coughtrie et al., 1988; Cui et al.,
2010). In rodents, Abcc transporter expression change with age (Maher et al.,
2005b; Cheng et al., 2007). In neonates and children, Phase II enzymes such
as UGTs expression is low compared to adults (Coughtrie et al., 1988).
Similarly drug transporters such as Abcc family transporters, have low hepatic
expression in neonates compared to adult mice (Maher et al., 2005b). In
rodents, gender dependent Abc transporter expression is observed in liver.
	
  

3

For example, Abcc4 is highly expressed in females compared to males (Maher
et al., 2005b).

In rats, age dependent differences in Phase-II and drug

transporter expression in neonates are taught to be responsible for cardiac
glycoside induced toxicity (Guo et al., 2002; Maher et al., 2005b). Low
expression of hepatic Abcc2 was taught to be one of the reasons for
occurrence of neonatal jaundice (Maher et al., 2005b).
2. Obesity:
Obesity is metabolic disease characterized with increased body mass index
(BMI≥30) (2010). Obesity is a hallmark disease of metabolic syndrome and
widely considered as a complex condition. There is growing concerns of
obesity affecting people worldwide and approximately above 30% of US
population was effected by obesity of which 5% are considered as morbidly
obese.

During obesity, fat accumulation in liver (steatosis) was observed

which represents non-alcoholic fatty liver (Wanless and Lentz, 1990). It is well
established that during obesity and other metabolic disorders several genes
expression changes take place particularly in liver. Few studies documented
the coordinate regulation of drug transporter and nuclear receptor expression
in steatosis. Altered nuclear hormone expression in fatty liver, was taught to
be one of the factors responsible for change in metabolic genes (Cheng et al.,
2008; More and Slitt, 2011).

Obesity and other metabolic syndrome

components are also characterized with altered levels of metabolism-related
hormones such as insulin, resistin, glucagon and amylin levels (Azuma et al.,
2003; Reinehr et al., 2007). Hyperinsulinemia was observed during obese
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and diabetic conditions. No studies have shown relation between metabolismrelated hormones role in regulating drug transporters. Recently, drugs that
target these metabolism-related hormones are developed for treating obesity
and diabetes (Schmitz et al., 2004). There is a need to identify whether these
metabolism-related hormones have role in regulating gene expression
changes particularly drug transporter expression during development of
obesity.
3. Leptin and rodent models of obesity:
There are of several models of obesity in rodents such as diet induced obesity
or genetically modified obseity. Ob/ob mice are genetically modified obese
model, these mice have a spontaneous mutation in Ob gene (leptin). Leptin a
hormone produced by adipose tissue both in human and rodent plays crucial
role in food consumption (Frederich et al., 1995; Kennedy et al., 1997). Leptin
regulates food consumption by acting on the central nervous system as a
negative feedback system for body fat accumulation (Elmquist et al., 1998;
Schwartz et al., 2000). Decreases in fat and body weight were observed with
leptin supplements in normal and mice lacking Ob gene (Muzzin et al., 1996;
Elmquist et al., 1998; Friedman and Halaas, 1998; Ahima and Flier, 2000;
Schwartz et al., 2000). Leptin levels in body correspond to amounts of fat
tissue. Leptin acts through membrane receptors (Ob-R), there are several sub
types of OB-R receptors they differs by length, location and functionality
(Kastin et al., 1999; Hileman et al., 2000; Martin et al., 2008). Obese Zucker
rat have mutated leptin receptor (fa, Ob-R gene), these rats display similar
	
  

5

conditions as ob/ob mice. Both in rodent and humans, there is an increase in
circulating leptin levels proportional to increase in adiposity in diet induced
obesity (Li et al., 1997) .

Ob-Re is a soluble leptin receptor isoform and

several other Serum Leptin Interacting Proteins (SLIPs) play crucial roles in
regulating leptin activity both centrally and peripherally (Lammert et al., 2001;
Zastrow et al., 2003; Chen et al., 2006). Leptin has no central action in
neonatal mice despite fact that there are high levels of circulating levels of
leptin. In neonates, high expression of OB-Re leptin receptor, which act as
leptin inhibitory protein was thought to be responsible for lack of leptin action
over CNS during that age (Ahima et al., 1998; Pan et al., 2008).

These

studies suggest that leptin has no or minimal regulation on food consumption
in neonates, which is contrary to leptin action in adults.
Adult ob/ob mice have well characterized models for obesity diabetes and
steatosis that is part of non-alcoholic fatty liver disease. Ob/ob mice have
characteristic

features

such

as

hyperphagia,

hyperglycemia,

glucose

intolerance, elevated plasma insulin, subfertility, hypometabolism and
hypothermia (Lindstrom, 2007).

All these physiological changes were

predominantly observed in ob/ob mice from four weeks of age (Dubuc, 1976).
Previous studies show that leptin has minimal or no central action until mice
are two weeks old; moreover ob/ob mice did not show any significant
physiological changes until they reach adolescence. This suggests neonatal
Ob mice should have normal physiological and gene expression changes as
normal mice. Drug transporter expression is known to alter during several
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metabolic conditions.

Both genetically modified and diet-induced obesity

alters drug transporter expression. Analyzing ontogeny of Ob mice hepatic
drug transporter expression will provide an insight how lack of leptin action
and increased levels of serum hormone levels can affect drug transporters
expression.
4. Bispheonl A:
Bisphenol A (BPA) is a monomer used in plastic manufacturing. According to
National Health and Nutrition Examination Survey, 92.6% of 2500 participants
have BPA in urine samples (Calafat et al., 2008).

BPA exposure during

gestation and lactation periods resulted in dysregulation of several aspects in
pups. The negative effects of BPA exposure are considered to be higher in
children compared to adults may be due to low expression of elimination
pathway. Adverse effects of BPA exposure includes increased body weights
in females, early onset of puberty, alterations in mammary glands and
reproductive glands, changes metabolic features, causes insulin resistance,
increases adipogenesis and predisposes to metabolic syndrome in pups
(Alonso-Magdalena et al., 2006; Somm et al., 2009; Wei et al., 2011). All
these adverse effects shown by BPA exposure involve multiple mechanisms,
such as epigenetic modulation and endocrine disruption.

In mice, methyl

donor supplementation along with BPA treatment has muted epigenetic
modulation shown by BPA (Dolinoy et al., 2007). BPA acts as an endocrine
disruptor by mimicking estrogen and binds to estrogen receptors (ER) such as
ER-alpha and beta. BPA is also known to act as an antagonist for thyroid
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hormone receptors. BPA developmental exposure in Avy mice has resulted in
change in coat color of pups through epigenetic modulation which was muted
by methyl donor supplementation along with BPA exposure (Dolinoy et al.,
2007).

BPA developmental exposure in these Avy mice altered sexual

dimorphic gene expression and sexual traits expressed in adult mice
(Jasarevic et al.; Mao et al.).
BPA is highly metabolized in gut and liver, and eliminated by urinary and fecal
excretion (Vandenberg et al., 2009).

Drug transporters play key role in

elimination of BPA from body, as they are involved in elimination of BPA
metabolites.

BPA-glucuronide and BPA-sulfate are the major metabolites

formed in humans and mice (Vandenberg et al., 2009). The Ugt2b family and
Sult1a1 enzymes are major biotransformation enzymes involved in BPA
conjugation (Nishiyama et al., 2002; Vandenberg et al., 2009).

Early

developmental toxicity caused by BPA in neonates may be due to low
expression of several Phase II enzymes compared to adults (Hines, 2008).
Decrease in these Phase-II and drug transporter expression in liver may cause
accumulation of BPA in body. BPA metabolite elimination differs from rodent
to human and non-human primates. In rodents, BPA primarily is excreted by
the biliary route whereas in human BPA undergoes urinary excretion
(Vandenberg et al., 2009).

Some in vitro studies performed in hepatic

carcinoma cells such as HepG2 cells showed BPA exposure has altered ABC
drug transporter expression (Hanet et al., 2008). To date, there are no studies
reported or performed showing effects of BPA exposure on hepatic drug
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transporters, yet transporters are vital to maintaining systemic levels of
circulating hormones. Disruption of hepatic transporter expression may be one
of the mechanisms by which endocrine disrupting compounds, such as BPA,
elicit hormone-disrupting effects.

Evaluating whether BPA developmental

exposure modulates hepatic drug transporter expression or not will provide
valuable information about how environmental toxicant exposure through
maternal diet affects pups xenobiotic and hormone metabolism.
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ABSTRACT
Purpose: Obesity is a predominant risk factor for metabolic syndrome, which is
defined as a cluster of risk factors that occur simultaneously and increase the
likelihood of coronary artery disease, stroke, and type-2 diabetes. One
manifestation of metabolic syndrome is the development of hepatic steatosis
in conjunction with insulin resistance. In recent years, the occurrence of
obesity in the adult population has significantly increased, which warrants the
need for better drug efficacy and toxicity prediction. The purpose of this
study was to determine whether clinical biomarkers and hormones could
correlate with nuclear receptor and transporter-related pathways at different
ages, in order to better predict altered drug metabolism or disposition.
Methods: Livers from male and female C57BL/6 and ob/ob mice littermates at
1, 3, 4 and 8 weeks of age were collected. Serum hormone and mRNA levels
were analyzed using a Luminex platform. Correlation between physiological
changes and gene expression was performed using canonical correlations.
Results: Significant ontogenic changes in both C57BL/6 and ob/ob mice were
observed during and post-weaning.

In males and females, the ontogenic

pattern started to differ from week 3, but significant changes were observed at
week 4 and 8 in ob/ob mice compared C57BL/6 mice. Significant correlations
were observed between physiological changes, hormones, and gene
expression changes during development of obesity.
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Conclusion: The correlation between physiological changes and gene
expression indicate metabolism-related hormones can regulate or be coregulated with genes involved in drug metabolism and transport. Specifically,
in males correlations indicate serum resistin and glucagon can regulate
hepatic Abc transporter expression.
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INTRODUCTION
Obesity is a metabolic disease characterized by an increased body mass
index (BMI≥30). Obesity is a predominant risk factor for metabolic syndrome
(MetS), which encompasses increase in body weight, adipose tissue mass,
insulin resistance, and serum hormone levels (Grundy, 2004). One of the
manifestations of metabolic syndrome is the development of hepatic lipid
accumulation (e.g. steatosis), which represents non-alcoholic fatty liver
disease (NAFLD) in conjunction with insulin resistance (Wanless and Lentz,
1990). There is a growing concern about absorption, distribution, metabolism,
and excretion (ADME) in the obese population, as studies reveal an altered
ADME in people affected with obesity and metabolic diseases (Brill et al.,
2012). Ob/ob mice have a mutation in the Ob gene that encodes for the
leptin, resulting in a phenotype that has many characteristics common to Mets.
Due to lack of leptin, ob/ob mice exhibit hyperphagia, profound weight gain,
hyperglycemia, glucose intolerance, elevated plasma insulin and severe
hepatic steatosis (Lindstrom, 2007).

Most of these changes are observed

predominantly in ob/ob mice from four weeks of age (Dubuc, 1976).
Drug transporters are membrane bound proteins that facilitate both uptake and
efflux of xenobiotics, endogenous compounds and their metabolites in various
tissues including liver.

Hepatic transporter expression is an important

determinant in maintaining systemic balance of endogenous compounds such
as bile acids, hormones, and bilirubin (Lecureux et al., 2009). ATP-binding
cassette (Abc) transporters are kind of drug transporters, which are ATP	
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dependent membrane proteins that transport a wide variety of compounds.
Multiple hepatic conditions can alter drug transporter expression, such as
obesity, oxidative stress, inflammation, drug-induced liver injury, and
environmental toxicants (Geier et al., 2003; Aleksunes et al., 2008; Cheng et
al., 2008). Previous studies document alterations in drug transporter and drug
metabolizing enzyme expression (DME’s) in obese and diabetic conditions
(Cheng et al., 2008; More and Slitt, 2011).
In liver, transcription factors, such as pregnane X receptor (Pxr, Nr1i2),
constitutive androstane receptor (Car, Nr	
   1i3), farnesoid X receptor (Fxr,
Nr1h4) and nuclear factor E2-related factor 2 (Nrf2, Nfe2l2) regulate the basal
and inducible expression of biotransformation enzymes and Abc transporters
(Klaassen and Slitt, 2005). For example, Pxr and Car upregulate Cyp3a11
and Cyp2b10 expression, whereas Nrf2 upregulates Nqo1 gene transcription
and expression (Aleksunes et al., 2006). With regard to transporters, hepatic
Abcc2-4 induction by microsomal enzyme inducers is observed to be Nrf2dependent (Maher et al., 2005a).

Prototypical Pxr activators upregulate

hepatic Abcc2, 3, Slc10a1 and Slco1a4 expression (Cheng et al., 2005b;
Maher et al., 2005a; Cheng et al., 2007), whereas Car activators upregulate
Abcc2-6 in liver (Cheng et al., 2005b; Maher et al., 2005a). However, the
mechanisms by which transcription factors regulate transporter expression
during development of fatty liver disease are largely not well described. An
increase in Pxr, Car and Nrf2 mRNA expression with no changes in binding to
consensus sequences was observed in livers of 9 week old ob/ob mice
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compared to C57BL/6 mice (Xu et al., 2012), suggesting other mechanisms
may be involved in the coordinate regulation of drug transporter and
transcription factor expression in steatosis.
Obesity alters levels of metabolic hormones, such as resistin, glucagon, insulin
and incretins (Starke et al., 1984; Azuma et al., 2003; Reinehr et al., 2007),
which could help explain the observed changes in gene expression. Known
consequence of obesity is insulin resistance accompanied by hyperglycemia
(Kahn et al., 2006).

Although increased incretin such as glucagon like

peptide-1 (GLP-1) levels are observed in obese people, GLP-1 activity
associated with insulin secretion is decreased compared to lean individuals
(Laferrere et al., 2007). Several therapies that target these hormones have
been identified for treatment of obesity and other metabolic diseases (Schmitz
et al., 2004).

During obesity correlations have been identified between

changes in serum resistin, leptin and insulin levels (Pantsulaia et al., 2007).
As more incretins based therapies are being utilized to manage diabetes a
component of Mets, it is critical to understand whether incretin hormones could
modulate drug disposition.
Ob/ob mice are commonly used to model MetS and fatty liver disease
(Lindstrom, 2007). This study aims to correlate typical clinical endpoints and
metabolic hormones with hepatic transcription factoes, prototypical drug
metabolizing enzyme (DME), and transporter mRNA expression. The findings
of this study provide potential insight into possible measures and serum
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biomarkers that can be used to predict potential ADME changes in obese
patients.
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MATERIALS AND METHODS
Animals and husbandry. Heterozygous mice were mated and offspring were
genotyped for sex and mutation of the leptin gene. Tissues from male and
female wild type (C57BL/6J) and homozygous (ob/ob) were collected at age of
week 1, 3, 4, and 8 (n=4-5 per group). Blood was collected and serum was
obtained after centrifugation at 5,000 rpm for 5 minutes at 4°C. Livers were
collected, snap frozen in liquid nitrogen, and stored at -80°C for future
analysis. All animal experiments were approved by University of Rhode Island
Institutional Animal Care and Use Committee (IACUC).
Hematoxylin and eosin staining. After collection, a small section of liver
from the central lobe was fixed in formaldehyde for 24 h and then transferred
to 75% ethanol prior to paraffin embedding. Paraffin-embedded tissues were
cut to approximately 5 micron sections, and stained with hematoxylin and
eosin by standard histology protocols (AML Laboratories, Rockland, MD).
RNA extraction. Total RNA from livers was isolated by phenol-chloroform
extraction method using RNA-Bee reagent (Tel-Test Inc., Friendswood, TX),
according to the manufacturer’s protocol. RNA concentration was quantified
by absorbance at 260 nm using a Nanodrop ND1000 (Thermo Fisher
Scientific, Waltham, MA) and the samples were diluted to 1 µg/µL.
Formaldehyde–agarose gel electrophoresis followed by UV illumination was
used to visualize RNA and confirm integrity.
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QuantiGene® multiplex suspension array. Mouse liver mRNA expression
was determined using a Quantigene® Plex 2.0 assay (Panomics Inc.,
Fremont, CA) with a Bio-Plex System Array reader with Luminex 100 xMAP
technology, and data was acquired using Bio-Plex Data Manager Software
(Bio-Rad, Hercules, CA).

Assays were performed according to the

manufacturer's protocol (Panomics, Inc.).
determined prior to running the assay.

The optimal RNA input was

Briefly, 500 ng of total RNA was

incubated overnight at 53°C with X-MAP beads containing oligonucleotide
capture-probes, label extenders, and blockers. On the next day, beads and
bound target RNA were washed and subsequently incubated with amplifier at
46°C for 1 hr.

Next, samples were washed and incubated with the label

(biotin) at 46°C for 1 hr.

Samples were washed and incubated with

streptavidin-conjugated R-phycoerythrin, which binds biotinylated probes, and
incubated at room temperature for 30 min.

Streptavidin-conjugated R-

phycoerythrin fluorescence was then detected for each analyte within each
sample. Data was normalized with the average week 1 expression in C57BL/6
mice and expressed as arbitrary units (AU).
Branched DNA amplification (bDNA) assay. Relative bile salt-export pump
(Abcb11, Bsep) and Na+-taurocholate cotransporting polypeptide (Slc10a1,
Ntcp)	
   mRNA levels were quantified using bDNA assay using previously
described probesets (Cheng et al., 2007). All reagents for analysis including
lysis buffer, amplifier/label probe diluent and substrate solution were supplied
in the QuantiGene 1.0 assay kit (Panomics, Fremont, CA). Briefly, the probe
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set stocks containing capture extenders, label extenders, and blockers were
diluted 1:100 in lysis buffer before use. On day one, total RNA samples (10
µg) were added to wells containing 50 µL of capture hybridization buffer and
50 µL of diluted probe set. The RNA was allowed to hybridize overnight with
the probe set at 53°C.

On day two, subsequent hybridization steps were

followed as detailed in the manufacturer’s protocol, and fluorescence was
measured with a GloRunnerTM microplate luminometer interfaced with
GloRunner DXL Software (Turner Biosystems, Sunnywale, CA).

The

fluorescence for each well was reported as relative light units (RLU) per 10 µg
of total RNA (Donepudi et al., 2012). Data was normalized with the average of
week 1 expression in C57BL/6 mice and expressed as arbitrary units (AU).
Serum metabolism-related hormone levels.

Serum metabolism-related

hormones were quantified using a Millipore 10-plex kit (MMHMAG-44K) on a
Bioplex® multiple array system.

A custom Millipore-plex kit containing

different targets such as insulin, glucagon, resistin, glucagon like peptide-1
(GLP-1), amylin and leptin was used and

analyzed according to

manufacturers protocol. Fluorescence was detected on a Bioplex® multiple
array reader system (BioRad, Hercules, CA). Data was collected by Bioplex®
manager 5.0 software and plotted as average concentration (µg/mL).
Correlation analysis. Correlations between the mRNA levels of genes related
to drug metabolism and transcription factors were performed using either
Statistica 9.1 software (Stat Soft, Inc., Tulsa, OK) or canonical correlation
analysis (CCA).
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was log transformed and distributed in 3 blocks such that block 1 contained
gene expression of drug transporters and phase I enzymes, block 2 contained
transcription factor expression, and block3 contained physiological dataserum hormone and, glucose levels, body and, liver weights. Cross block
pairwise bivariate correlations were performed between each block and heat
maps were generated. Hierarchical clustering was performed using the same
data with pearson correlation. Data presented as heat maps or with r value,
p≤0.05 is considered as a statistically significant correlation.
Statistical analysis.

The statistical significance between groups was

determined by factorial ANOVA followed by a Duncan’s Multiple-range post
hoc test, using Statistica 9.1 software (Stat Soft, Inc., Tulsa, OK). Data are
presented as mean ± SE, with p ≤0.05 considered statistically significant.
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RESULTS
Tissue and body weights, blood glucose levels: Figure 1A illustrates the
body weights of male and female C57BL/6 and ob/ob mice. At week 1 of age,
body weight was similar between all groups. At weeks 4 and 8, ob/ob mice
had significantly higher body weight compared to C57BL/6 mice, as
anticipated. Figure 1B illustrates serum glucose levels each group of mice. A
2.3-fold age-dependent increase in serum glucose levels was observed at 8
weeks

compared to week1 C57BL/6 mice.

In male ob/ob mice, serum

glucose levels increased with age at week 4 and 8 by 2.1 and 4.5-fold
respectively, compared to week 1 ob/ob male mice. In female ob/ob mice,
serum glucose levels increased with age at week-3, 4 and 8 by 1.7, 1.9 and
3.8-fold respectively compared to week 1 female ob/ob mice. Serum glucose
levels in both male and female ob/ob mice were significantly increased at
week 8 compared to C57Bl/6 counterparts by 1.3-fold, these changes in serum
glucose levels between ob/ob mice and C57BL/6 mice were not observed at
early ages.
Ontogeny of serum hormones in C57BL/6 and ob/ob mice. Figure 1C
illustrates serum hormone changes observed in both male and female
C57BL/6 and ob/ob mice from weeks 1, 3, 4 and 8. Serum hormone levels
were similar between C57BL/6 and ob/ob mice at one week of age. In male
C57BL/6 mice, glucagon, resistin and GLP-1 decreased with age, but insulin
and amylin did not. In male C57BL/6 mice, serum glucagon, resistin, and
GLP-1 levels were decreased by ~78% from week 3 compared to week 1.
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However, in male ob/ob mice, serum insulin and amylin increased with age
after week 4 by 4-fold. Also, serum insulin, glucagon, resistin, GLP-1 and
amylin levels were significantly elevated in male ob/ob mice compared to male
C57BL/6 mice from 4 weeks of age.
In female C57BL/6 mice serum glucagon, resistin and GLP-1 levels decreased
with age. However, serum insulin and amylin levels were similar at all weeks
assessed.

In female ob/ob mice, insulin and amylin increased after four

weeks of age while glucagon, resistin, and GLP-1 levels decreased by 57%,
31% and 40% respectively, compared to 1 week old female ob/ob mice.
Similar to observations in males, all serum hormone levels were increased at 8
week time point in females ob/ob mice compared to corresponding C57BL/6
females.
Transporter and prototypical metabolizing enzyme expression livers of
C57BL/6 and ob/ob mice. Figure 2 illustrates hepatic efflux drug transporter
expression observed in both male and female C57BL/6 and ob/ob mice. In
C57BL/6 and ob/ob mice ontogenic changes were observed in Abc transporter
expression for Abcc1, 3, 4, 5 and Abcb11 in both males and females. Similar
to physiological changes, no significant changes were observed in Abc
transporters expression between one-week old male and female C57BL/6 and
ob/ob mice. In male ob/ob mice, Abcc3, 4 and Abcg2 mRNA expression was
increased significantly compared to C57BL/6 mice by 1.8, 7 and 2.3-fold
respectively.

A similar increase was observed in female ob/ob mice, with

Abcc3, 4 and Abcg2 mRNA expression compared to female C57BL/6 mice. In
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contrast to males, female ob/ob mice have significant decrease in Abcb11
mRNA expression by 49% compared to female C57BL/6 mice. Most of these
significant changes in both male and female ob/ob mice were observed from 4
weeks of age.
Figure 3 illustrates hepatic uptake drug transporter expression in both male
and female C57BL/6 and ob/ob mice. In both male and female C57BL/6 mice,
Slco1a1 expression increased significantly at week 8 compared to week 1 by
219 and 95-fold respectively. However these changes in Slco1a1 mRNA levels
were not observed in both male and female ob/ob mice. Interestingly, in 8week old male and female ob/ob mice, Slco1a1 expression was significantly
decreased by 97 and 98% respectively, compared to their C57BL/6
counterparts. In male and female, C57Bl/6 and ob/ob mice, ontogenic
changes in Slco1a4 were observed only at 3 and 4 weeks of their age but not
in week 8 old mice compared to week 1.
Figure 4 illustrates hepatic DME expression observed in both male and female
C57BL/6 and ob/ob mice. In male and female ob/ob mice Cyp2b20 and 4a14
mRNA expression significantly increased with age compared to week 1
whereas no ontogenic changes were observed in C57BL/6 mice. Changes in
mRNA expression with age in Cyp3a11 were observed from 3 weeks of age
whereas changes in Cyp2b20 and 4a14 mRNA expression were observed
from 4 weeks of age.

Male ob/ob mice also showed a significant increase in

cyp2b20 and 4a14 expression from 4 weeks of age compared to their
C57BL/6 counterparts by 4.3 and 2.2-fold respectively. Female ob/ob mice
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had significant increase in expression of Cyp3a11 (1.3 fold) and Cyp2b20 (1.8
fold) expression compared to C57BL/6 mice at only week-4. Cyp4a14 mRNA
expression in female ob/ob mice significantly greater at both 4 and 8 weeks by
2.5 and 3.1-fold respectively compared to female C57BL/6 mice.
Hepatic transcription factor expression of C57BL/6 and ob/ob mice.
Figure 5 illustrates the hepatic transcription factor mRNA expression levels in
livers of male and female C57BL/6 and ob/ob mice. In male C57BL/6 and
ob/ob mice, there were no significant ontogenic changes in transcription factor
mRNA expression, except Nrf2 and Ppar-α. In male ob/ob mice, Nrf2 mRNA
expression increased at week-8 by 2 fold compared to week-1. At week-8,
Car, Fxr and Nrf2 mRNA expression significantly increased by 2-3 fold, in
male ob/ob compare to male C57BL/6 mice. In female C57BL/6 mice, Pxr
mRNA expression decreased with age by 51% compared to week-1, however
this is not observed in female ob/ob mice. In female ob/ob mice, only Fxr
mRNA levels significantly increased by 2.5 fold at 3 and 4 weeks of their age
compared to week-1. In females no significant changes were observed in
transcription factors expression between ob/ob and C57BL/6 mice.
Correlation

analysis

between

gene

expression

changes

and

phenotypical changes. Role of gender and leptin in ontogenic changes in
hepatic gene expression pattern is depicted pictorially using heat maps (Figure
6 & 7). Gene expression values were log transformed to generate heat maps
using R-language. These heat maps strongly indicate leptin and gender plays
a huge role in the regulation of hepatic genes involved in metabolism and
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disposition. Difference in ontogenic changes in ob/ob mice and C57BL/6 mice
in both male and female illustrates influence of leptin over peripheral tissues
apart its regulation of satiety at central nervous system. Table 1 & 2 illustrates
correlations between physiological factors, such as metabolic hormone levels,
serum glucose, and body and liver weights were performed using canonical
correlations. Canonical correlations were performed to identify physiological
factors, which may have a potential role as a biomarker during development of
obesity (Table 1 & 2). In males, serum resistin and insulin levels correlate with
all physiological factors, whereas in female mice, serum resistin, insulin and
amylin correlate with other physiological factors during development of
obesity. In both males and females, these correlations between physiological
factors suggest that changes in serum resistin levels may be associated with
development of obesity irrespective of gender.
Furthermore, canonical correlations were performed between physiological
factors and gene expression to identify relationships between changes in gene
expression during development of obesity and common parameters used to
assess MetS. Figure 8 illustrates correlations for physiological factors such as
hormone level, body, and liver weights with drug transporter and DME
expression in male and female mice presented as heat maps. In males and
females, serum amylin levels correlated with Abcc4, Abcg2, Cyp2b20 and
4a14 expression. Correlation between other physiological factors and drug
transporters expression differ between males and females.

For example,

serum resistin levels correlated with Abcc1, 4, 5, Abcb1a, Abcb11, Slco1a1,
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Cyp3a11 and 4a14 expression in male mice, whereas resistin levels correlated
to Abcc1, Abcb11, Slco1a1, 1a4, Slc10a1, Cyp3a11, 2b20 and 2e1 in females.
Furthermore, serum insulin concentrations correlated to Abcc4, Abcg2,
Cyp2b20 and 4a14 expression in males whereas it is correlated to Abcc4,
Abcg2 and Slco1a1 expression in females. Serum glucagon concentrations
correlated with Abcc1, 4, Abcg2, Abcb1a, Abcb11, Slco1a1, Cyp3a11 and
Cyp4a14 expression in males, but correlated to Abcc6, Abcb11, Slco1a4, 1b2
and Slc10a1 expression in females. In males, serum GLP-1 concentrations
were correlated with only Abcb11, Slco1a4, Cyp3a11 and 2e1 expression
whereas in females it is correlated with Abcc2, 3, Abcb11, Slco1a1, 1a4, 1b2,
Cyp3a11, 2b20 and 2e1 expression. In males, serum glucose concentrations
correlated to Abcc1, 3, 5, 6, Abcb1a, Abcb11, Cyp3a11 and 2b20 expression
whereas it is correlated only to Abcc3-5, Cyp3a11 and 2b20 in females. Both
body and liver weights correlated to Abcc1, 3, 5, 6, Abcb1a, abcb11, Slco1a1,
Cyp3a11 and 2b20 expression in male mice, whereas in females they
correlated with Abcc1, 3- 6, Cyp3a11 and 2b20 expression.
Figure 9 illustrates the correlation (heat maps) between transcription factors
with drug transporters and phase I enzymes expression in male and female
mice. Correlation between transcription factors, drug transporters, and DME
expression was performed using canonical correlations and the data
generated is presented as a heat map.

In males, during development of

obesity and MetS, expression patterns of all Abc transporters except Abcb11
were correlated with all transcription factors analyzed with minor exceptions.
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In male mice, Abcc3 expression did not correlate with Pxr, Car, Ppar-α, and
Ppargc1α expression, whereas Abcc5 is not correlated with Fxr. Correlation
between Abc transporters and transcription factors showed gender dependent
changes during development of obesity. Interestingly, in female mice only
Abcc2, 6 and Abcb1a expression was correlated with all transcription factors
analyzed, whereas Abcg2 expression was correlated with all transcription
factors except Car during development of obesity. In female mice, Abcc3
expression was correlated to Car, Lxr, Fxr and Nrf2 expression, whereas
Abcc4 expression was correlated to Pxr, Lxr, Fxr and Nrf2 expression. In both
male and female mice, uptake transporter Slco1b2 expression was correlated
to all transcription factors expression whereas Slco1a4 expression was
correlated with Car, Lxr, Fxr, Nrf2 and Ppargc1α expression.

Drug

metabolizing enzymes such as Cyp2e1 and 4a14 expression was correlated
with all transcription factors expression in both male and female mice. In male
mice, Cyp2b20 expression was correlated to Lxr, Fxr and Nrf2 expression
whereas in females Cyp3a11 and 2b20 were correlated to Car, Lxr, Fxr and
Nrf2 expression.
DISCUSSION
Obesity and the subsequent MetS are major concerns in the United States
(Grundy, 2004). Non-alcoholic fatty liver disease (NAFLD) is a manifestation
of MetS. About 15-39% of the US population is affected with NAFLD, and
about 95% of the morbidly obese are diagnosed with NAFLD (Younossi et al.,
2002; Collantes et al., 2004).
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NAFLD because they have multiple markers that are elevated in a manner
similar to humans with uncontrolled MetS – morbid obesity, markedly elevated
glucose levels, insulin resistance and dysregulation of metabolic hormones,
dyslipidemia, increased markers of inflammation, and hepatic steatosis
(Lindstrom, 2007). Studies have shown alteration in drug transporter and drug
metabolizing enzyme expression during NAFLD, which resulted in altered drug
elimination (Barshop et al.; Lickteig et al., 2007; Cheng et al., 2008; Hardwick
et al., 2012).

Moreover, changes in hepatic uptake and efflux transporter

expression in ob/ob mice is somewhat similar to changes observed in dietinduced obese mice and human steatotic livers (Cheng et al., 2008; More and
Slitt, 2011).
Previous studies have shown that expression of several DMEs and drug
transporters in C57BL/6 mice change with age (Cheng et al., 2005a; Maher et
al., 2005b; Cui et al., 2010).

In this study we characterized ontogeny of

transporters along with phase-I enzymes in coordination with transcription
factors in both C57BL/6 and ob/ob mice. We selected four different ages (e.g.
week-1, 3, 4 and 8) to capture different times during the progression of MetS.
Ontogeny of drug transporters in both male and female C57BL/6 mice we
observed are similar to published studies (Cheng et al., 2005a; Maher et al.,
2005b).

Changes observed in transporters, phase-I enzymes, and

transcription factors expression in ob/ob mice compared to C57BL/6 mice
were similar to published studies (Cheng et al., 2008; Xu et al., 2012).
As mentioned earlier ob/ob mice have characteristic physiological changes. At
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week-1 body and liver weights do not show any significant difference from
their lean counterparts.

However, increased body and liver weight were

observed with development of obesity in ob/ob mice irrespective of gender
(Figure 1A and 11). These observations with body and liver weights are
consistent with previously published studies (Dubuc, 1976). In ob/ob mice,
similar to body and liver weight changes, hyperglycemia developed with
development of obesity. Liver histology was similar at week-1, steatosis was
observed at week-3, but prominent changes in histology presented at week-4
(Figure

12).

Metabolic-related

hormones

concentrations

altered

with

development of obesity although their concentrations are similar to lean
littermates at early ages.

Interestingly, correlations between physiological

changes showed serum resistin and insulin levels have significant correlations
in both males and female mice during development of obesity. Resistin is
circulating protein secreted by adipose tissue, which plays an important role in
causing insulin resistance (Steppan and Lazar, 2002). In diet-induced obese
mice, administration of anti-resistin antibody corrected hyperglycemia and
insulin resistance, which are key factors for causing obesity (Steppan and
Lazar, 2002). Our results from correlation analysis also indicates changes in
serum resistin levels can be a possible biomarker, which can predict changes
liver gene expression associated with MetS.
Incretins, like amylin and GLP-1, play a key role in insulin secretion and
maintaining blood glucose levels. In both male and female ob/ob mice, GLP-1
levels were changed at week-8, whereas amylin levels increased from week-4.
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Amylin is secreted along with insulin from pancreas and involved in
maintaining serum glucose levels (Moreno et al., 2011). Changes in amylin
and insulin levels in our study were observed at same time.

Moreover,

changes in amylin and insulin levels along with resistin showed significant
correlation with other physiological parameters analyzed in females during
development

of

obesity.

As

mentioned

by

Reinehr

et

al

2007,

hyperamylinemia was thought to be one of the important factors in causing
several metabolic abnormalities during obesity and MetS (Reinehr et al.,
2007). Recently new incretin based drug therapies for MetS such as amylin
and GLP-1 agonists are gaining importance (Schmitz et al., 2004). Correlation
observed in our study indicates alteration in incretin levels may alter several
physiological factors and hepatic metabolism-related gene expressions
eliciting need to consider possible changes in xenobiotic metabolism and
disposition in people undergoing multiple medications along with incretin
based therapies.

Post market studies Indicates, that patient under GLP-1

agonist therapies has 1.93 fold increase in occurrence of biliary infections
such as

cholelithiasis, which can be caused due to altered hepatic Abc

transporter expression. Correlation observed in our study and post market
analysis of incretin based therapies support that possibility of hepatic drug
transporter regulation by metabolic hormones.

Abc transporters comprise the majority of hepatic efflux pumps, which efflux
compounds from hepatocytes into bile or blood (Faber et al., 2003). In adult
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mice livers, relative Abcc1 and 4 are low, whereas Abcc3 expression is
moderate, and Abcc6 is high (Maher et al., 2005b). In both C57BL/6 and
ob/ob mice, Abcc1 and 5 are expressed highly at week1 and decreased with
age. This pattern of high expression at initial stages and decrease at later age
period in expression of Abcc1 is also observed in liver regeneration after
undergoing 90% hepatectomy, indicating Abcc1 to have a lesser role in adult
liver (Kimura et al., 2012).

Abcc3 is highly inducible basolateral efflux

transporter that can cause altered vectorial disposition of xenobiotics (Slitt et
al., 2003). Abcc3 and 4 play key role in efflux of several xenobiotics and
endogenous compounds such as estrogen and bile acid conjugates. Abcc 4
protects hepatocyte from bile acid toxicity during cholestatic conditions
(Mennone et al., 2006). In both male and female C57BL/6 mice there is a
slight increase although not statistical difference was observed in Abcc3 and 4
expressions with age. In both males and females obesity increased Abcc3
and 4 mRNA levels with age as well as compared to their lean littermates.
Apical efflux transporters such as Abcc2, Abcg2, Abcb1a and Abcb11 plays
major role in excretion of xenobiotics and endogenous substances from liver to
bile. In both male and female mice, Abcc2 and Abcb1a mRNA levels are
unaltered with age and obesity.

Previous studies indicated no change in

mRNA levels and increase in protein levels of Abcc2 in ob/ob mice, which is
consistent with our results (Cheng et al., 2008). Abcc2 expression during
obesity is species specific; in obese zucker rats Abcc2 expression decreases
whereas it increases in ob/ob mice, but in humans there is no change with
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obesity (Pizarro et al., 2004; Cheng et al., 2008; More and Slitt, 2011). In
male ob/ob mice Abcb11 expression did not alter compared to their lean
littermates whereas in females Abcb11 expression decreased with progression
of obesity. Gender specific difference in Abcb11 expression pattern may be
due to gender specific difference in growth hormone responsiveness in obesity
(Cocchi et al., 1993) which is known to regulate Abcb11 expression (Cheng et
al., 2007).

Previous studies showed that Abc transporter expression is

regulated by several transcription factors (Maher et al., 2005a). Interestingly,
significant correlations were observed between hepatic Abc transporters and
transcription factors expression during development of obesity.

These

correlations during development of obesity between transcription factors and
hepatic efflux transporters showed gender dependent changes.

Gender

dependent changes in correlation between Abc transporters and transcription
factors are much more pronounced in week-8 mice (Table 3 and 4).
Hepatic uptake transporter Slco1a1 mRNA levels increased with age in
C57BL/6 mice whereas in ob/ob mice it remained unchanged. In both male
and female ob/ob mice Slco1a1 mRNA levels decreased significantly at week8. Previous studies shown Slco1a1 mRNA expression is androgen dependent
and negatively regulated by microsomal enzyme inducers that activate
transcription factors Pxr, Car, Ppar-α and Nrf2 (Lu et al., 1996; Cheng et al.,
2005b). Ob/ob mice have decreased androgen levels (Swerdloff et al., 1976)
and increase in transcription factors

expression (Xu et al., 2012), which

explain decrease in Slco1a1 expression compared to C57BL/6 counterparts as
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they become old. Moreover in males, at week-8 age Slco1a1 expression was
negatively correlated with all transcription factors that are analyazed, although
these correlations are not significant (Table 3). Obesity did not affect the
ontogeny of Slco1a4, 1b2 and Slc10a1, which is contrary to previously
published studies.

Differences in our results are may be due to age,

previously published studies showed altered hepatic Slco1a4, 1b2 and
Slc10a1 expression in week-11 old mice (Cheng et al., 2008), moreover
hepatic uptake transporters are shown to change their expression pattern with
age (Fu et al., 2012).
Several studies have shown correlations and alteration in serum hormone
levels during metabolic disorders. Studies also showed hormones such as
estrogen, progesterone and androgens could alter hepatic uptake and efflux
transporter expression (Geier et al., 2003; Kalabis et al., 2007). No studies
have documented correlation with change in drug transporter expression with
metabolism-related hormones, which are known to change in obesity. Acute
or chronic administration of metabolism-related hormones such as glucagon
and GLP-2 altered transporter expression and function. GLP-2 an incretin
secreted along with GLP-1, which acts majorly on intestines was shown to
regulate Abcc2 expression in intestine (Villanueva et al., 2010). In human and
rat hepatocytes, short-term glucagon treatment altered Abcc3 function
(Chandra et al., 2005). Not only transporters but also phase-II enzymes such
as glutathione transferases expression were altered with glucagon and insulin
treatment (Kim et al., 2003), indicating metabolism related hormones have a
	
  

40

potential to alter drug metabolism and related gene expression. In males,
serum resistin, glucagon and glucose levels are correlated with most of
hepatic Abc transporter expression compared to serum amylin, insulin and
GLP-1 levels.

In females, serum glucose showed more correlations with

hepatic Abc transporter expression than serum metabolism-related hormones.
Apart from serum metabolism related hormones and glucose levels, body and
liver weights have shown high correlation with all hepatic Abc transporters
analyzed (Figure 8). Not only hepatic Abc transporters but overall, serum
glucose, and body and liver weight stood as a markers for change in gene
expression and physiological factors during development of obesity (Figure
10). In females, during development of obesity hepatic uptake transporter
mRNA expressions were correlated with serum levels of resistin, glucagon and
GLP-1 (Figure 8B).

These correlations indicate that not only sex related

hormones such as estrogen and testosterone (Lu et al., 1996; Geier et al.,
2003) but also hormone involved in energy metabolism such as resistin,
glucagon and GLP-1 have a role in regulation hepatic uptake transporters.
Phase-I DMEs such as Cyp3a11 and 2e1 were not altered with obesity.
Cyp2e1 expression during obesity and diabetes is species-specific.

In

humans, Cyp2e1 is increased during obesity and diabetes whereas in mice it
either remained unchanged or decreased (Enriquez et al., 1999; Wang et al.,
2003; Cheng et al., 2008). In both male and female ob/ob mice Cyp4a14
expression increased with development of obesity. Cyp4a plays a key role in
fatty acid metabolism and is shown to be upregulated in adult male ob/ob mice
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(Cheng et al., 2008).

In males, Cyp2b20 mRNA levels increased with

development of obesity compared to C57BL/6 mice whereas in female
Cyp2b20 mRNA levels remained unchanged. These gender specific changes
in Cyp2b20 are observed in other model such as treatment with phenobarbital,
which is an inducer of Cyp2b family (Larsen et al., 1994; Cheng et al., 2008).
Insulin treatment altered Cyp3a, 2e1 and 4a expression in hepatocytes (Kim et
al., 2003), indicating metabolism-related hormones can regulate phase-I
enzyme expression. Our results indicated that in female mice Cyp enzyme
expression during development of obesity is mostly correlated to resistin and
GLP-1, whereas in males these correlations are variable. Sexually dimorphic
regulation of Cyp enzymes might be responsible for gender specific
differences in expression and correlations with metabolism related hormones
(Hernandez et al., 2009).
In summary, ob/ob mice are indistinguishable from their lean littermates at
week-1. Interestingly, during week1 in both male and females there are no
significant changes in transporter, DME’s and transcription factors mRNA
levels. Not only mRNA levels, even physiological changes such as steatosis,
metabolism-related hormone levels, body and liver weight are similar between
ob/ob and C5BL/6 mice at week-1.

In both males and females, although

ontogeny pattern started to differ from week-3 in ob/ob mice compared
C57Bl/6 mice, significant changes were observed in week-4 and 8.
IConsistent with previous studies, significant changes in physiological factors
like hyperglycemia and insulin resistance were observed after weaning
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(Dubuc, 1976; Lindstrom, 2007). Correlation in drug transporters and DME’s
expression with metabolism-related hormones in a model of obesity and MetS
indicates changes in these hormones can alter ADME of xenobiotics and
endogenous compounds. Although physiological changes analyzed did not
show up as a biomarker for prediction in gene expression changes, the
correlation indicated that metabolism-related hormones analyzed were either
co-regulated or involved in regulation of hepatic gene expression, which needs
further investigation. Finally, this study gives an idea about how changes in
expression of drug metabolism related genes could occur at different stages of
obesity and diabetes development.
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Figure 1. Effect of age and leptin deficiency on phenotypical changes in
C57BL/6 and ob/ob mice.

(A) Body weights of both male and female,

C57BL/6 and ob/ob mice at week1, 3, 4 and 8. (B) Serum glucose levels of
both male and female, C57BL/6 and ob/ob mice at week1, 3, 4 and 8. Serum
glucose concentration was determined by glucose assay kit.

Data is

presented as average concentration (mg/dl) ± S.E.M. (n=4-5 mice per group).
(C) Metabolism-related hormone levels of both male and female, C57BL/6 and
ob/ob mice at week1, 3, 4 and 8.

Metabolism-related hormone levels in

C57BL/6 and ob/ob mice were quantified in serum collected from female and
male C57BL/6 and ob/ob mice at 1, 3, 4, and 8 weeks of age (n= 4-5 for each
group). Hormones were quantified using a luminex-based assay. Data is
presented as average concentration (µg/ml)±S.E.M. (n=4-5 mice per group).
Asterisks (*) represent a statistical difference between wild type and ob/ob of
same age group and pound (#) represent a statistical difference with respect
to week-1 mice (p≤0.05).
Figure 2.

Effect of age and leptin deficiency on hepatic Abc drug

transporters expression in both C57BL/6 and ob/ob mice. Total RNA was
isolated from livers of wild-type and ob/ob mice. Hepatic ATP-binding cassette
(Abc) transporter mRNA levels was quantified by the QGP 2.0 Plex assay.
Data is presented as mean arbitrary units (AU) ± S.E.M. (n=4-5 mice per
group). Data presented as mean arbitrary units (AU) ± S.E.M. (n=4-5 mice per
group). Asterisks (*) represent a statistical difference between wild type and
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ob/ob of same age group and pound (#) represent a statistical difference with
respect to week-1 mice (p≤0.05).
Figure 3. Effect of age and leptin deficiency on hepatic uptake drug
transporters expression in both C57BL/6 and ob/ob mice. Total RNA was
isolated from livers of wild-type and ob/ob mice. Hepatic uptake transporter
such as organic anion transport polypeptides (Oatps, Slco’s) and Na+taurocholate cotransporting polypeptide (Slc10a1, Ntcp) mRNA levels was
quantified by the QGP 2.0 Plex assay. Data is presented as mean arbitrary
units (AU) ± S.E.M. (n=4-5 mice per group. Asterisks (*) represent a statistical
difference between wild type and ob/ob of same age group and pound (#)
represent a statistical difference with respect to week-1 mice (p≤0.05).
Figure 4.

Effect of age and leptin deficiency on hepatic drug

metabolizing enzymes (DME) expression in both C57BL/6 and ob/ob
mice.

Total RNA was isolated from livers of wild-type and ob/ob mice.

Hepatic DME’s such as Cyp3a11, 2e1, 2b20 and 4a14 expression was
quantified with QGP 2.0 plex assay. Data presented as mean arbitrary units
(AU) ± S.E.M. (n=4-5 mice per group). Asterisks (*) represent a statistical
difference between wild type and ob/ob of same age group and pound (#)
represent a statistical difference with respect to week-1 mice (p≤0.05).
Figure 5. Effect of age and leptin deficiency on hepatic transcription
factors expression in both C57BL/6 and ob/ob mice.

Total RNA was

isolated from wild type and ob/ob mice livers, mRNA expression of Pxr, Car,
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Lxr, Fxr, Nrf2, Ppar-α and Ppargc1α was analyzed with QGP 2.0 plex assay.
Data presented as mean arbitrary units (AU) ± S.E.M. (n=4-5 mice per group).
Asterisks (*) represent a statistical difference between wild type and ob/ob of
same age group and pound (#) represent a statistical difference with respect
to week-1 mice (p≤0.05).
Figure 6. Heat maps for gene expression analysis performed in both
male C57BL/6 and ob/ob mice. Hepatic gene expression values from week1, 3, 4, and 8, C57BL/6 and ob/ob mice are log transformed and heat maps
were generated using g-plots in R language.
Figure 7. Heat maps for gene expression analysis performed in both
female C57BL/6 and ob/ob mice.

Hepatic gene expression values from

week-1, 3, 4, and 8, C57BL/6 and ob/ob mice are log transformed and heat
maps were generated using g-plots in R language.

Figure 8.

Correlation (heatmaps) between physiological factors with

hepatic drug transporters and DME’s expression during development of
obesity in male (A) and female (B) mice. Hepatic gene expression from
week-1, 3, 4, and 8, C57BL/6 and ob/ob mice are log transformed and data
set was divided into two blocks. Block-1 contains hepatic drug transporters
and DME’s expression and block-2 contains hepatic transcription factors
expression.

Correlations between block-1 and 2 were performed using

canonical correlations. Data displayed as heat maps with highest positive
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correlations considered as black and highest negative correlation are
considered as red
Figure 9. Correlation (heatmaps) between transcription factors with drug
transporters and DME’s expression during development of obesity in
male (A) and female (B) mice. Hepatic gene expression and physiological
factors such as body, and liver weights, serum metabolism-related factors
such as insulin, glucagon, resistin and amylin levels from week-1, 3, 4, and 8,
C57BL/6 and ob/ob mice are log transformed. Log transformed data set was
divided into two block such that one of the block contains hepatic gene
expression drug transporters and DME’s expression and other block contains
physiological factors. Correlations between both block were performed using
canonical correlations. Data displayed as heat maps with highest positive
correlations considered as black and highest negative correlation are
considered as red
Figure 10. Hierarchical clustering of log transformed variables using
Pearson correlation as a similarity measure.

Gene expression of drug

transporters, DMEs and physiological factors was correlated with each other.
Hierarchical clustering was performed using canonical correlations.	
  
Figure 11. Effect of age and leptin deficiency on liver weights in C57Bl/6
and ob/ob mice. Liver weight of both male and female, C57Bl/6 and ob/ob
mice at week1, 3, 4 and 8.
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between wild type and ob/ob of same age group and pound (#) represent a
statistical difference with respect to week-1 mice.
Figure 12. Effect of age and leptin deficiency on liver pathology.

A)

Representative liver pathology in male C57Bl/6 and ob/ob mice at week 1, 3,
4, and 8 (n=1 for each group). B) Representative liver pathology in female
C57Bl/6 and ob/ob mice at week 1, 3, 4, and 8 (n=1 for each group).
Representative photomicrographs of Hematoxylin and Eosin stains of liver
sections (200x).
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Table 1. Correlation matrices for variables in phenotypical factors during
development of obesity in male mice. Data presented as r values, * value
indicates significant correlation (p≤0.05).
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Table 2. Correlation matrices for variables in phenotypical factors during
development of obesity in female mice. Data presented as r values, * value
indicates significant correlation (p≤0.05).
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Table 3. Correlation of hepatic transcription factors expression with
hepatic drug transporters and DME’s expression in adult (week-8 old)
male mice.

Data presented as r values, * value indicates significant

correlation (p≤0.05).

	
  

Male

Pxr

Car

Lxr

Fxr

Nrf2

Ppar-α Ppargc1a

Abcc1

0.95*

0.97*

0.98*

0.98*

0.93*

0.99*

0.95*

Abcc2

0.90*

0.98*

0.97*

0.92*

0.89*

0.97*

0.96*

Abcc3

0.96*

0.91*

0.93*

0.97*

0.95*

0.94*

0.94*

Abcc4

0.91*

0.83*

0.90*

0.93*

0.91*

0.87*

0.89*

Abcc5

0.89*

0.96*

0.93*

0.91*

0.86*

0.95*

0.91*

Abcc6

0.65*

0.73*

0.62

0.58

0.51

0.65*

0.68*

Abcg2

0.97*

0.97*

0.97*

0.99*

0.93*

0.98*

0.96*

Abcb1a 0.81*

0.71*

0.81*

0.80*

0.85*

0.76*

0.80*

Bsep

0.11

-0.02

-0.02

0.08

0.03

-0.01

Slco1a1 -0.35

-0.15

-0.33

-0.39

-0.49

-0.29

-0.27

Slco1a4 0.91*

0.97*

0.99*

0.93*

0.93*

0.98*

0.96*

Slco1b2 0.28

0.50

0.39

0.30

0.30

0.41

0.43

Ntcp

0.30

0.26

0.42

0.44

0.28

0.28

0.01

0.47
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Table 4. Correlation of hepatic transcription factors expression with
hepatic drug transporters and DME’s expression in adult (week-8 old)
female mice.

Data presented as r values, * value indicates significant

correlation (p≤0.05).

Fxr

Nrf2

Ppar-α Ppargc1a

-0.68* -0.05

-0.30

-0.05

-0.61

-0.62

0.64

0.57

0.68*

0.48

0.60

0.79*

0.49

Abcc3

0.25

-0.28

0.81*

0.49

0.89*

0.23

0.07

Abcc4

-0.02

-0.54

0.67*

0.20

0.76*

-0.08

-0.28

Abcc5

0.17

0.35

0.24

0.42

0.20

0.42

0.67*

Abcc6

0.66

0.94*

0.03

0.18

-0.09

0.76*

0.63

Abcg2

0.21

-0.39

0.79*

0.41

0.81*

0.11

-0.19

Abcb1a 0.82*

0.52

0.61

0.28

0.48

0.72*

0.48

Bsep

0.35

-0.35

0.11

-0.38

0.15

0.41

Slco1a1 0.48

0.86*

-0.22

0.27

-0.43

0.59

0.39

Slco1a4 0.18

0.38

-0.14

0.33

-0.20

0.29

0.55

Slco1b2 0.65

0.63

0.51

0.72

0.46

0.82*

0.82*

Ntcp

0.35

-0.22

-0.27

-0.17

0.15

0.30

Female Pxr

Car

Abcc1

-0.60

Abcc2

0.09

0.31

Lxr
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ABSTRACT
BPA is a synthetic xenostrogen used in plastic manufacturing. Multiple studies
in rodents demonstrate that developmental BPA exposure results in
physiological, behavioral,and gene expression changes through multiple
mechanisms – including epigenetic modifications. However, the impact of
developmental BPA exposure on liver function was less known; as liver being
a crucial determinant for systemic hormone concentrations and, chemical
detoxification and clearance. The purpose of this study was to investigate the
effect of developmental BPA exposure on the expression of hepatic Phase-II
and Abc transporter expression involved in liver clearance processes and BPA
metabolism. Female C57BL/6 (a/a) mice were fed either low or high dose of
BPA (50 µg or 50mg/kg diet) or ethinyl estradiol (EE) (0.1ug/kg diet) or BPA
(50mg/kg diet) with genistein (250 mg/kg diet) or AIN93 Control diet with 7%
corn oil from 2 weeks pre-mating with male Avy/a mice. BPA exposure was
maintained through the breeding and lactation period. Livers were collected
from male offsprings after PND 135. Developmental exposure to BPA and EE
downregulated hepatic drug transporters and Phase II enzyme expression,
involved

in

BPA

metabolism

and

excretion

whereas,

genistein

co-

administration reversed these changes. Decrease in Nrf2 mRNA expression
and binding activity could be partially responsible for downregulation of
hepatic Phase II enzymes and drug transporter expression. Further, increase
in expression of Hdacs upon BPA exposure could be responsible for
decreased transcription factor expression and activity. Our data suggest that
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developmental BPA and EE exposure may work via similar pathways, and
greatly affect the expression of key hepatic genes involved in BPA and
hormone metabolism and clearance.
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INTRODUCTION
The liver is the major organ for metabolism and clearance; with a significant
role in determining circulating systemic endocrine hormone and bile acid
concentrations. Hepatic clearance of chemicals (e.g. hormones, drugs, and
chemicals of exposure) relies upon several families of membrane-associated
transport proteins working in concert with Phase-I and –II biotransformation
enzymes.

Numerous

enzymes

including

Cytochrome

P450s,

UDP-

glucuronosyl transferases (Ugts) and sulfotransferases (STs) are involved in
biotransformation processes in liver. The resulting glucuronide and sulfate
metabolites typically undergo fecal and urinary excretion through bile or blood
via transporter-dependent mechanisms localized to the canalicular or
basolateral membrane of hepatocytes, respectively.
Transporters are membrane proteins, which facilitate chemical transport into
and out of cells (Klaassen and Aleksunes, 2010). In liver, the ATP-binding
cassette (Abc) superfamily of transporters are involved in excretion of
endogenous and xenobiotic compounds from the body, as well as
enterohepatic recirculation of bile acids.

Membrane transporter proteins are

crucial in facilitating the uptake and biliary excretion of endogenous chemicals
(e.g. conjugated hormones, bile acids, and conjugated bilirubin), and
xenobiotics (e.g. environmental chemicals and drugs) (Faber et al., 2003).
Changes in certain transporters can cause imbalance in endogenous
chemicals, such as bile acids, endocrine hormones, and bilirubin (Lecureux et
al., 2009). Moreover, xenobiotic metabolism is considered to be less efficient
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without drug transporters (Faber et al., 2003).

Impairment of certain drug

transporters function, such as Multidrug resistance-associated protein 2 (Mrp2,
Abcc2) and Bile salt-export pump (Bsep, Abcb11), cause hyperbilirubinemia
and cholestasis respectively (Faber et al., 2003). During different pathological
and physiological conditions, such as cholestasis or acetaminophen-induced
liver injury, Abc transporter expression in liver is altered (Slitt et al., 2007;
Aleksunes et al., 2008).
Bisphenol A (BPA) is a monomer used in plastic manufacturing. According to
National Health and Nutrition Examination Survey, 92.6% of 2500 participants
have BPA in urine samples (Calafat et al., 2008). Perinatal BPA exposure to
Avy mice disrupted sexual dimorphic gene expression and sexual trait
expression in adult mice (Mao et al., 2010; Jasarevic et al., 2011). In utero
BPA exposure increased body weights in females altered mammary and
reproductive glands, changed metabolic features, caused insulin resistance,
increased adipogenesis, and predisposed to metabolic syndrome in pups
(Alonso-Magdalena et al., 2006; Somm et al., 2009; Wei et al., 2011). BPA
exposure is emerging as a well-studied example of the “fetal basis of disease”.
The fetal basis of adult disease hypothesis proposes that various factors, such
as nutrition or environmental exposure during prenatal and early postnatal
development can affect development, resulting in susceptibility to chronic
disease as an adult (Dolinoy et al., 2007b).

Adverse effects elicited by

developmental BPA exposure involve epigenetic mechanisms through
modulation of DNA and histone methylation and endocrine disruption
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(Vandenberg et al., 2009; Kundakovic and Champagne, 2011). For example,
BPA perinatal exposure in Avy mice changed the coat color of pups through
epigenetic modulation via DNA hypomethylation, which was dampened by
genestein supplementation along with BPA exposure (Dolinoy et al., 2007a).
BPA also acts as an endocrine disruptor by mimicking estrogen and binds to
estrogen receptors (ER, such as ER-alpha and beta. BPA is also known to act
as a thyroid hormone antagonist (Moriyama et al., 2002).
BPA is highly metabolized in liver and eliminated by urinary and fecal
excretion (Pottenger et al., 2000; Volkel et al., 2002). BPA glucuronide (BPAGluc) and -sulfate (BPA-S) are the major metabolites formed in humans and
mice (Pottenger et al., 2000; Volkel et al., 2002). The UGT2B family and
SULT1A1 enzymes are major biotransformation enzymes involved in BPA
conjugation (Nishiyama et al., 2002; Hanioka et al., 2008). In rodents, Abcc2
is the predominant transporter, which mediates BPA-Gluc excretion from liver
into bile (Inoue et al., 2005). Maternal exposure to other endocrine disruptors,
such as polybrominated diphenyls (PBDEs) and BDE47 alters expression of
metabolic enzymes and ABC transporters (Richardson et al., 2008; Szabo et
al., 2009).
This study aimed to identify whether developmental BPA exposure could affect
hepatic clearance processes, such as metabolism and disposition, in
adulthood. In this study two different doses of BPA were administered; 50
µg/kg diet and 50 mg/kg diet (equivalent to 6.5 µg/kg body weight and 6.5
mg/kg bodyweight respectively) (Rosenfeld et al., 2013).
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Along with BPA

exposure, dams were also exposed to ethinyl estradiol as a positive control or
co-administrated genestein with BPA as previously described (Dolinoy et al.,
2007a; Rosenfeld et al., 2013). Overall, the results herein detail that maternal
exposure to BPA during gestation and lactation decreased hepatic transporter
expression in male offsprings that were 135 days or older, which was in
association with decreased recruitment of Hdac to the Abbc2 and 3 promoter.
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MATERIALS AND METHODS
Animals and treatments:

All animal experiments including breeding and

dietary exposure were conducted by Dr. Cheryl Rosenfeld’s laboratory at
University of Missouri Columbia according to the IACUC regulations at the
University of Missouri Columbia as previously described (Rosenfeld et al.,
2013). Livers from this study (Rosenfeld et al., 2013) were used for the study
herein..

Animal exposure and breeding was performed as previously

described by Rosenfeld et al., 2013 (Rosenfeld et al., 2013). Briefly, virgin
females (C57Bl/6, a/a) were fed one of the following five diets 1) Corn oil
(control), 2) BPA 50 µg/ Kg diet (low dose), 3) BPA 50mg/Kg diet (high dose),
4) Ethniyl estradiol (EE), 0.1 µg/ Kg diet, 5) BPA 50mg/Kg and Genistein
250mg/Kg diet (BPA-G).

Dams were fed the diet through gestation and

lactation period. Pups were weaned and fed control diet, such that they were
exposed to BPA only during the period of gestation and lactation. Livers were
collected from male pups after postnatal day 135 days (n=5-6 per group).
RNA Isolation and cDNA Synthesis: Total RNA was isolated with RNAzol B
reagent (Tel-Test Inc., Friendswood, TX). RNA concentration was assessed
using NanoDrop™ (UV absorbance was measured at 260 nm) and the
integrity was confirmed by formaldehyde gel electrophoresis.

The mRNA

samples were stored at -80°C until further use for analysis. cDNA for each
sample was synthesized from 1µg of total RNA using cDNA synthesis Kit
according to the manufacturer’s protocol (Roche®, Germany).
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qPCR Analysis: Gene expression was analyzed using Real-time quantitative
PCR. qPCR was carried out using SYBRH Green PCR Master Mix (Roche®,
Germany) with a Light Cycler 480 II (Roche®, Germany). Details of primers
used were mentioned in Table 1.
Microsomal preparation:

200mg of liver tissue (n=3-6 per group) was

washed with ice-cold saline and 50mM sodium pyrophosphate buffer (pH-7.4).
Following washing livers were homogenized in 600 µl homogenizing buffer
(0.25M Sucrose, 50mM Tris-Hcl (pH-7.8), 0.5mM EDTA, 20µM BHT, 0.1mM
DTT) and centrifuged at 10,000x g for 15 min.

The supernatant were

centrifuged again at 100,000x g for 60 min. The resulting cytosols were stored
at -80°C for future use. The microsomal pellet was re-suspended in buffer
(0.25M Sucrose, 10mM Tris-Hcl (pH-7.8), 1mM EDTA, 20µM BHT and 20%
glycerol) and stored at -80°C for future use.
Enzymatic BPA Glucuronidation and analysis:

Hepatic microsomal

fractions (0.0075mg) were incubated with 1µM BPA and 2mM UDPGA in
50mM phosphate buffer (pH-7.0) for 30 min at 37°C. At the end of Incubation,
tubes were heated in boiling water to deactivate protein and centrifuged at
14000Xg for 10 min. Supernatant were collected and injected in to HPLC.
BPA and BPA-Gluc were analyzed using HPLC-UV (System Gold®, Beckman
Coulter, Inc.). 50 µl of each sample was injected onto column (ZORBAX SBAq, 5µm, 4.6X150mm, Agilent Technologies). A gradient elution used with
80% ACN and 20% 20mM phosphate buffer (pH-2.7) at 1 ml/min flow rate
(Wen et al., 2013) and analyzed at 200nm using an system Gold® UV detector
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168 (Beckman Coulter, Inc).

BPA and BPA-Gluc were identified using

standards of BPA (Sigma-Aldrich) and BPA-Gluc (Toronto research chemicals,
Canada) made in 50mM phosphate buffer (pH-7.0). BPA-Gluc and BPA are
eluted at 7.4 and 10 minutes respectively. BPA and BPA-Gluc were quantified
by comparing area of peak with BPA and BPA-Gluc standard curves (Wen et
al., 2013).
Nuclear protein extraction: Nuclear extracts were isolated from liver tissue
using Pierce NE-PER® nuclear extraction kit (Thermo Fisher Scientific,
Rockford, IL, USA) and protein concentration was determined by the DC
protein assay (Bio-Rad, Inc.).
Western Blotting:

Western blots for transporters and nuclear histone

deacetylase (Hdac), were performed according to previously published
methods (Aleksunes et al., 2008; Donepudi et al., 2012).

50 µg nuclear,

cytosolic, or crude membrade protein was loaded per well, and proteins were
electrophoretically separated by a 4-20% SDS PAGE gel and transblotted onto
PVDF membrane. Blots were blocked with 5% non-fat dry milk in TBST. The
blots were incubated with primary antibody overnight, washed in TBST, and
then incubated with secondary antibody for an hour. Staining was visualized
by autoradiography. Antibodies details are Abcc2 (M2III-5, Enzo Life Sciences,
Farmingdale, NY), Abcc3 (M3II-2), Abcc4 (M4I-10), Abcg5 (BXP-53) from G.
Scheffer laboratory (VU Medical Center, Amsterdam, The Netherlands), Bsep
(K44), Ntcp (K4) from B. Steiger laboratory (University Hospital, Zurich,
Switzerland), Hdac and Gadph (Cell signaling, MA, USA).
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Transcription factor binding assay: Nuclear extracts obtained from livers
were quantified for transcription factor binding to a prototypical ARE
consensus sequence using a Procarta TF 9-plex custom array (Affymetrix,
CA) according to the manufacturer’s instructions and quantified using a Biorad
Bioplex, which utilizes a luminex platform (Xu et al., 2012a).
Hepatic bile acid levels:

Hepatic bile acids were extracted from using

tertiary-butanol extraction method and quantified as described previously
(Donepudi et al., 2012) using a bile acid assay kit (Bioquant, San Diego, CA,
USA).
Hepatic Glutathione levels: Hepatic reduced glutathione (GSH) levels were
measured using GSH-GloTM Glutathione assay kit (Promega). Briefly, 20mg of
liver tissue was homogenized in 2ml of 2mM EDTA in phosphate buffered
saline (PBS) and homogenate was centrifuged.
was analyzed for hepatic glutathione levels.

The resulting supernatant
Hepatic GSH levels were

analyzed according to manufacturer’s protocol. Luminescence was measured
using a GloRunnerTM microplate luminometer interfaced with GloRunner DXL
Software (Turner Biosystems, Sunnywale, CA, USA).
Dibromosulfophthalein (DBSP) disposition: DBSP (120mmole/kg/5ml, i.p.)
was injected into mice. Mice were euthanized 45 min after DBSP injection and
DBSP concentration was determined in gallbladder bile.

Concentration of

DBSP was quantified spectrophotometrically at 575 nm after alkalinization of
the samples with 0.1M NaOH.
Statistical Analysis: The statistical significance between groups was
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determined using one-way ANOVA followed by a Duncan’s post hoc test,
using Statistica 9.1 software (Stat Soft Inc., Tulsa, OK, USA).

Data are

presented as mean ± SE, with P ≤0.05 considered statistically significant.
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RESULTS
Effect of developmental exposure of BPA on Body and liver weights.
Figure 1 illustrates body and liver weights of male pups, which have
undergone developmental exposure of BPA, EE and BPA-G. Body weights
were similar among BPA, EE and BPA-G developmental exposure in pups.
Similar to body weights, exposure to the various diets did not change the liver
weights.
Effect of developmental exposure of BPA on Phase-II conjugation. Figure
2A illustrates the effect of developmental BPA exposure on hepatic BPA
glucuronidation.

In rodents, Ugt2b1 and Sul1a1 are Phase-II enzymes

involved in BPA metabolism (Yokota et al., 1999; Nishiyama et al., 2002).
Both BPA and EE developmental exposure decreased Ugt2b1 expression in
pups to 35 and 31%, and Sult2a1 mRNA levels by 48 and 27 % of control dietexposed pups respectively.

BPA-Gluc is the predominant BPA metabolite

formed by humans and rodents, formed through glucuronidation (Yokota et al.,
1999). Figure 2B illustrates the effect of BPA developmental exposure on
hepatic BPA glucronidation capacity at a relatively low BPA concentration.
Similar to mRNA levels of Ugt2b1, BPA glucuronidation levels decreased with
BPA developmental exposure.

BPA high dose and EE developmental

exposure decreased BPA glucuronidation in pups to about 74% and 81% of
control, respectively.

Genistein co-administration reversed the observed

decrease caused by BPA developmental exposure. The BPA concentration (1
µm) in the reaction vessels was chosen because it is a more relevant
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concentration and lower or as low as previously described (Wen et al., 2013).
The observed percent decrease in BPA glucuronidation is less than the
observed decrease in Ugt2b1 expression, and this is likely due to the low
concentration of BPA used, which is less than Km (Mazur et al., 2010).
Effect of developmental exposure to BPA on hepatic basolateral drug
transporter expression. Figure 3 illustrates effect of BPA developmental
exposure on hepatic basolateral drug transporter expression in pups. Hepatic
basolateral drug transporters such as Abcc3, 4, and Ntcp expression
decreased with BPA developmental exposure. These observed changes were
similar to EE exposure, whereas the effects caused by BPA developmental
exposure were not observed with genistein exposure.

In pups, with both

doses of BPA exposure Abcc4 and Ntcp mRNA levels decreased about to 21
and 31 % of controls,whereas Abcc3 mRNA levels in livers of adult sons had a
decreasing trend with BPA exposure.

Developmental exposure to EE

decreased Abcc3, 4, and Ntcp mRNA levels about to 21, 2 and 26 %, of
controls respectively. Similar to mRNA levels, developmental BPA exposure
decreased protein expression of Abcc3 and 4.

Ntcp protein expression

decreased with both doses of BPA and increased with EE exposure compared
to the control diet group despite decreased mRNA levels.
Effect of developmental exposure to BPA on apical drug transporter
expression. Figure. 4 illustrates the effect of BPA developmental exposure on
expression of canalicular drug transporter expression in livers of adult male
sons. In livers of adult male sons, with both doses of BPA exposure Abcc2,
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Abcg2, and Bsep mRNA levels were decreased to 54, 40 and 41 % of control
diet-exposed group respectively.

EE developmental exposure decreased

Abcc2, Abcg2, and Bsep mRNA levels about to 36, 20 and 22% of control diet
group respectively. Similar to mRNA levels, BPA developmental exposure
decreased Abcc2 protein expression in liver. Abcg2 protein expression was
similar to controls and unaltered with BPA and EE exposure, EE exposure
increased Bsep protein expression, whereas Bsep expression was similar
between BPA exposed and control groups.
Developmental BPA exposure perturbs bile acid and GSH levels in liver.
Hepatic Abc transporters are determinants for the excretion and enterohepatic
circulation of bile acids.

Altered hepatic Abcc2 expression was observed

during cholestasis (Geier et al., 2003), a pathological condition caused by
impedence of bile acids leading to bile acid accumulation in liver. Exposure to
the low BPA dose significantly increased hepatic bile acid concentration by
30% compared to controls, but not at the higher BPA dose. Abcc2 transports
utilizes GSH as cofactor to drive biliary excretion. Moreover Abcc2-/- mice
have increased hepatic total glutathione levels (Chu et al., 2006).

BPA

exposure increased GSH levels in liver by 60 and 80%, respectively,
compared to concentrations on livers of controls (Figure 5B).
Effect of developmental exposure of BPA on DBSP disposition. DBSP
disposition is used as a estimation of hepatic transport function (Dhumeaux et
al., 1974) and targeted Abcc2 deletion significantly decreased DBSP levels in
mice (Chu et al., 2006), illustrating DBSP as a substrate for mouse Abcc2.
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Both BPA exposures significantly reduced DBSP levels in bile to 24 and 33%,
of control diet group respectively (Figure 5C).

The observed decrease in

DBSP concentration in gallbladder bile likely reflects the corresponding
decrease in liver Abcc2 expression.
Developmental BPA exposure decreases transcription factor expression
and binding. Figure 6 illustrates the effect of developmental BPA exposure
on gene expression and binding activity of transcription factors involved in
regulation of drug transporters and Phase-II enzymes.

In rodents,

transcription factors such as Ahr, Car, Fxr and Nrf2 are known to regulate drug
transporters and Phase-II enzyme expression (Rushmore and Kong, 2002;
Nakata et al., 2006). BPA, at both concentrations, decreased Ahr, Car, Fxr
and Nrf2 mRNA levels in livers of adult sons by at least 41, 36, 53 and 58%,
respectively, which was similar to EE developmental exposure. Conversely,
the decrease in hepatic transcription factor expression was not observed in
livers from pups that had maternal dietary genistein supplementation.

In

contrast to mRNA expression, transcription factor such as Ahr, Car and Fxr
binding activity was unaltered at the lower BPA concentration fed to dams.
However, the higher BPA dose and EE developmental exposure decreased
Ahr, Car, and Fxr binding activity.

Both BPA exposures decreased Nrf2

binding, which was not observed in livers from pups from dams fed BPA with
genestein.
Developmental BPA exposure increases Class 1 Hdac expression. In
order to determine a mechanism by which decreased biotransformation,
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transporter, and nuclear receptor expression occurs, it was hypothesized that
developmental BPA exposure might affect pathways with panoramic effects of
gene transcription.

Hdacs are known to modulate or down regulate

expression genes such transporters. Figure 7 illustrates Class I Hdac protein
expression in nuclear extracts obtained from livers of adult sons from dams
that were fed control, BPA, EE, or BPA-G diet. Class I Hdac proteins such, as
Hdac 1, 2 and 3, nuclear levels was increased with both doses of BPA and EE
developmental exposure compared to control group.

Genistein co-

administration slightly increased Hdac1, 2 and 3 nuclear levels but not to the
level of BPA and EE developmental exposure groups.
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Discussion:
BPA a xenoestrogen present ubiquitously in the environment (Vandenberg et
al., 2009), and is known to cause several adverse effects (Vandenberg et al.,
2009). BPA exposure in humans is variable as studies report different values
of estimated human exposure (Vandenberg et al., 2009).

Toxicological

studies identify 1000 mg BPA/kg body weight (BW)/day as maximum tolerable
dose in humans (Vandenberg et al., 2009).

According to EPA, the daily

tolerable intake or no observed adverse effect levels (NOAEL) of BPA is 50
µg/kg BW/ day (Vandenberg et al., 2009). In this study, two concentrations
BPA were supplemented in maternal feed, one below NOAEL, one higher than
the NOAEL.

Several studies documented, in rodent models, that BPA

exposure is associated with physiological, behavioral and gene expression
changes at or below NOAEL (Alonso-Magdalena et al., 2006; Somm et al.,
2009; Jasarevic et al., 2011; Wei et al., 2011; Patisaul et al., 2012), indicating
BPA can causes several adverse effect below NOAEL.
Despite liver being important for elimination of endocrine disrupting
compounds and determining systemic hormone levels, few studies address
the effect of BPA on hepatic processes like metabolism.

BPA undergoes

extensive Phase-II conjugation, which is essential for decreasing BPA body
burden (Volkel et al., 2002) and conjugated BPA does not have endocrine
disruption effects caused by BPA (Matthews et al., 2001). BPA primarily
undergoes glucuronidation, whereas sulfonation can occur, but is considered
to have a minor, but appreciable role (Pottenger et al., 2000). Species-specific
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differences were observed in BPA elimination pathways. In rodents, BPAGluc primarily undergoes biliary excretion whereas in humans, BPA
undergoes urinary excretion (Vandenberg et al., 2009). In vitro studies using
ATPase assays have identified ABCC3 in humans as a possible drug
transporter involved in transport of BPA-Gluc (Mazur et al., 2012), whereas in
rodents Abcc2 is major transporter of BPA-Gluc (Inoue et al., 2005).
In the present study, the effects of developmental exposure of BPA on liver
function and hepatic metabolic processes in adult were documented.
Developmental BPA exposure downregulated key enzymes and transporters
involved in BPA metabolism and excretion. Developmental BPA exposure
also decreased activity or function of genes involved in BPA metabolism and
excretion. Effects observed in this study by developmental BPA exposure are
similar to EE developmental exposure although there were no changes in
estrogen levels in these mice (Figure 10). BPA and EE developmental
exposure significantly down-regulated hepatic Phase II enzymes such as
Ugt2b1 and Sult1a1, and hepatic efflux drug transporters such as Abcc2, 3,
and 4 expressions. Developmental BPA and EE exposure also decreased
BPA glucuronidation capacity of pups, which supports decrease in Phase II
enzyme expression in liver. Decrease in hepatic efflux transporters, primarily
Abcc2 expression was supported by increase total hepatic glutathione levels
and decrease of DBSP levels in bile. As mentioned previously, glutathione
conjugates and DBSP are substrates for Abcc2 (Chu et al., 2006).
Interestingly, changes in hepatic gene expression such Phase II enzymes and
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Abc transporter expression due to developmental BPA exposure was reversed
by genistein co-administration. Serum BPA levels in dams were unaltered
with

genistein

supplementation

(Figure

8),

indicating

genistein

co-

administration did not changed BPA exposure to dams and effects shown by
genistein co-administration did not involve differences in BPA exposure.
Decrease in hepatic metabolism genes and transcription factors by BPA
developmental exposure in this study were supported by similar observation in
CD-1 male pups, which are exposed to BPA at perinatal, and peripubertal
stages (Figure 11).
Our results shows, both doses of developmental BPA and EE exposure
downregulated transcription factor expression such as Ahr, Car, Fxr, and Nrf2,
and binding activity at high dose of BPA and EE developmental exposure.
Only Nrf2 binding activity to its consensus sequence was decreased with both
doses of BPA developmental exposure similar to Phase II and drug transporter
expression changes caused by BPA. This indicates Nrf2 role in BPA or EE
induced downregulation of hepatic drug transporters and Phase II enzymes in
pups. Decrease in Nrf2 expression and activity was supported by decrease in
its target gene Nqo1 expression (data not shown).
Hepatic Ugt2b1is a key enzyme involved in conjugation of endogenous
androgens and xenobiotics (Yokota et al., 1999). Although Phase II enzymes
particularly Ugt2b1 expression is minimally induced with transcription factors
activators, Nrf2-nullmice showed significant decrease in Ugt2b1 expression
indicating basal levels of Ugt2b1 expression is regulated by Nrf2 (Buckley and
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Klaassen, 2009; Reisman et al., 2009).

In mice, Sult1a1 expression is

significantly upregulated by only butylated hydroxyanisole (BHA), which is an
activator for Nrf2. In or study also decrease in Sult1a1 and Ugt2b1 expression
is similar decrease in Nrf2 expression and binding activity indicating BPA
induced downregulation of Phase II enzyme expression caused through
repression of Nrf2 activiy.
Studies have shown that hepatic efflux transporters such as Abcc2, 3 and 4
expression are regulated by several transcription factors such Ahr, Car and
Nrf2 (Maher et al., 2005). In mice, prototypical activators of these transcription
factors increase hepatic efflux transporter expression (Maher et al., 2005). In
mice, activation of Nrf2 by oxidative stress and chemical activators increased
hepatic Abc transporters expression such as Abcc2, 3 and 4.

Moreover,

hepatic efflux transporters such as Abcc2, 3, 4 and Abcg2 expression
decrease significantly in Nrf2-null mice whereas there expression significantly
increased in Keap1 knock down and Keap1 heaptocyte knockout mice
(Reisman et al., 2009; Wu et al., 2012).

Similar to these studies,

developmental BPA at both doses and EE exposure decreased hepatic efflux
transporter expression and only Nrf2 expression and activity in same pattern,
indicating Nrf2 role in BPA induced down regulation of hepatic Abcc2, 3 and 4
transporters.
In mice, developmental BPA exposure is known to induce epigenetic changes
such as hypomethylation and histone modification in different tissues at
different promoter regions (Kundakovic and Champagne, 2011). Epigenetic
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changes specifically hypomethylation of intracisternal A particle (IAP)
retrotransposon of agouti promoter region caused by developmental BPA
exposure is reversed with methyl donor and genistein supplementation
(Dolinoy et al., 2007a). Moreover, as mentioned earlier effects observed in
this study by BPA are similar to EE indicating these changes are caused due
to endocrine component involved in it which is known to cause epigenetic
changes in pups (Vandenberg et al., 2009).

In our study we observe a

decrease in methyl cytosine levels in genomic DNA isolated from liver with
developmental exposure of BPA although these changes are not reversed
with genistein co-administration (Figure 9).

Apart from DNA methylation,

histone modification such as methylation and acetylation also can regulate
nuclear receptor inducible gene transcription (Biddie, 2011). Hdac proteins
are known to remodel chromatin structure and act as co-repressors for nuclear
receptor inducible gene transcription (Biddie, 2011). Results presented in this
study showthat developmental BPA and EE exposure increased nuclear Hdac
levels whereas genistein co-administration did not as much as BPA. Increase
in class I Hdac nuclear levels indicate decrease in nuclear receptor inducible
gene transcription. In vitro studies had shown role of class I Hdac proteins in
regulation of efflux transporter expression (To et al., 2008; Xu et al., 2012b).
Moreover studies have shown that Hdac proteins can regulate Nrf2 induced
transcription and expression (Yu et al., 2010; Lee et al., 2012). In accordance
to previous studies and our results, we think developmental BPA and EE
exposure decrease hepatic gene expression by increasing Hdac levels and

	
  

95

decreasing nuclear receptor inducible gene transcription in pups.
Developmental BPA exposure decreases hepatic Phase II and drug
transporter expression in pups similar to EE exposure and is reversed by
genistein co-administration.

The observations from current study indicate

changes in Phase II enzymes and drug transporter expression due to
developmental BPA exposure was due caused by partly due to epigenetic
effects such as increase in class I Hdac nuclear levels and down regulation of
transcription factors. Decrease in hepatic genes such as drug transporter and
Phase II enzymes, which are involved in metabolism and elimination of
endogenous hormones and xenobiotics can alter drug and hormonal
metabolism.

Most importantly altered hepatic gene expression that are

involved in metabolism due developmental BPA exposure are persistent and
are caused below and above NOAEL, which supports BPA can cause adverse
effects at very low doses (Vandenberg et al., 2009). Hepatic Phase II and
drug transporter that are altered with developmental exposure of BPA are also
involved in hormone metabolism and elimination, changes in these gene
expression might be responsible for endocrine disruption caused by BPA.
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Figure Legends
Figure 1. Effect of developmental BPA exposure on body and liver
weights. Both BPA and EE developmental exposure did not affect body and
liver weights of male pups. Data is presented as average weights (grams) ±
S.E.M. (n=5-6 mice per group). An asterisk (*) represents a statistical
difference between pups from control diet fed dams to pups from BPA and EE
exposed dams (p≤0.05).
Figure 2. Effect of developmental BPA exposure on Phase II enzymes,
expression and activity, which are involved in BPA metabolism. Total
RNA was isolated from livers of male pups that are developmentally exposed
to either of diets such as control, BPA 50µg/kg and 50mg/kg, EE and BPA-G.
(A) Hepatic phase II enzymes such as Ugt2b1 and Sult1a1 mRNA levels were
quantified by quantitative PCR.

Data was normalized to 18S rRNA and

presented as a mean arbitary units + S.E.M. (n=5-6 mice per group). (B)
Enzymatic glucuronidation activity in male pups. Hepatic microsomes were
isolated from frozen liver tissue. BPA glucuronidation assays were carried out
with 1 µM BPA and BPA glucuronide formed was analyzed using HPLC. Data
presented as mean BPA glucuronide formed (nmoles/mg/min) + S.E.M. (n=3-7
mice per group). An asterisk (*) represents a statistical difference between
pups from control diet fed dams to pups from BPA, EE and BPA-G exposed
dams (p≤0.05).
Figure 3. Effect of developmental BPA exposure on hepatic basolateral
transporter expression. Total RNA was isolated from livers of male pups
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that are developmentally exposed to either of diets such as control, BPA
50µg/kg and 50mg/kg, EE and BPA-G. (A) Hepatic basolateral transporter
such as Abcc3, 4 and Ntcp mRNA levels were quantified by quantitative PCR.
Data was normalized to 18S rRNA and presented as a mean arbitary units +
S.E.M. (n=5-6 mice per group).

An asterisk (*) represents a statistical

difference between pups from control diet fed dams to pups from BPA, EE and
BPA-G exposed dams (p≤0.05).

(B) Protein quantification of hepatic

basolateral drug transporters using western blots. Data presented in order of
control, BPA 50µg/kg and 50mg/kg, EE and BPA-G diet and n=2 per group.
Figure

4.

Effect

of

developmental

BPA

exposure

on

hepatic

apical/canalicular transporter expression. Total RNA was isolated from
livers of male pups that are developmentally exposed to either of diets such as
control, BPA 50µg/kg and 50mg/kg, EE and BPA-G.

(A) Hepatic

apical/canlicular transporter such as Abccc2, Bsep (Abcb11) and Abcg2
mRNA levels were quantified by quantitative PCR. Data was normalized to
18S rRNA and presented as a mean arbitary units + S.E.M. (n=5-6 mice per
group). An asterisk (*) represents a statistical difference between pups from
control diet fed dams to pups from BPA, EE and BPA-G exposed dams
(p≤0.05). (B) Protein quantification of hepatic basolateral drug transporters
using western blots. Data presented in order of control, BPA 50µg/kg and
50mg/kg, EE and BPA-G diet and n=2 per group.
Figure 5. Effect of developmental BPA exposure on hepatic clearance.
Changes in endogenous and xenobiotic disposition caused due to
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developmental BPA exposure in pups. (A) Hepatic bile acid levels in male
pups from dams exposed to BPA. Hepatic bile acid were quantified and data
was presented as average concentrations (µmole/l/mg) + S.E.M. (n=5-6 mice
per group).

(B) Hepatic total glutathione levels in male pups from dams

exposed to BPA. Hepatic total glutathione levels were quantified and data
was presented as average concentrations (nmole/mg) + S.E.M. (n=5-6 mice
per group). (C) DBSP disposition in male pups from dams exposed to BPA.
DBSP levels in gall bladder was analyzed and data presented as
concentration (Molar/g of gall bladder) + S.E.M. (n=3-6 mice per group). An
asterisk (*) represents a statistical difference between male pups from control
diet fed dams to pups from BPA, exposed dams (p≤0.05) and (#) was
indicated for statistical significance of p=0.06.
Figure 6. Effect of developmental BPA exposure on transcriptional
factors expression and binding activity. Total RNA was isolated from livers
of male pups that are developmentally exposed to either of diets such as
control, BPA 50µg/kg and 50mg/kg, EE and BPA-G. (A) Transcription factors
such as Ahr, Car, Fxr and Nrf2 mRNA levels were quantified by quantitative
PCR. Data was normalized to 18S rRNA and presented as a mean arbitary
units + S.E.M. (n=5-6 mice per group). (B) Transcription factor binding activity
of Ahr, Car, Fxr and Nrf2 was analyzed using TF procarta assay. Data
presented as mean multiple fluorescence index (MFI) for n=2 samples per
group. An asterisk (*) represents a statistical difference between pups from
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control diet fed dams to pups from BPA, EE and BPA-G exposed dams
(p≤0.05).
Figure 7. Effect of developmental exposure of BPA on nuclear levels of
class I Hdac proteins and Hdac recruitment. (A) Protein quantification of
nuclear Hdac1, 2 and 3 levels was performed using western blots. Data
presented in order of EE, control, BPA 50µg/kg and 50mg/kg, and BPA-G diet
and n=1 per group. Developmental BPA and EE exposure increased nuclear
levels of class I Hdac proteins in pups.
Figure 8. Serum BPA levels in dams exposed to different diets. Data was
presented as average total BPA concentration (ng/ml) ± S.E.M (n=4-6 mice
per group). An asterisk (*) represents a statistical difference between pups
from control diet fed dams to pups from BPA, EE and BPA-G exposed dams
(p≤0.05).
Figure 9. Effects of developmental BPA exposure on global methylation
in male pups livers.

Total genomic DNA was isolated from livers and

analyzed for methylated cytosine levels using methylation kits (Epigentech).
Data was presented as average percentage of (5-methyl cytosine) ± S.E.M
(n=5-6 mice per group). An asterisk (*) represents a statistical difference
between pups from control diet fed dams to pups from BPA and BPA-G
exposed dams (p≤0.05).
Figure 10. Effects of developmental BPA exposure on serum estrogen
levels in male pups. Serum estrogen levels are determined using serum
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estrogen ELISA kit (Calbiotech, CA, USA). Data was presented as average
concentration (pg/ml) ± S.E.M (n=5-6 mice per group).
Figure 11. Effects of developmental BPA exposure on hepatic phase II
and drug transporter expression in male CD-1 pups. Female CD-1 mice(12
weeks old) were bred at Tufts University Human Nutrition, Boston, MA. . On
gestational day (GD) 6 dams were weighed and osmotic pumps (model 1004;
Alza Corp., Palo Alto, CA, USA) with flow rate 0.11µl/hr were implanted into
pregnant moms on GD 8 such that pups receive either vehicle (50% DMSO) or
two BPA (25, 250 µg/kg BW/ day) treatments.

Pups are weaned and

maintained on ad libitum diet. Post weaning pups were exposed to similar
BPA doses through drinking water.

Tissues from female offspring were

collected on postnatal day 32. Total RNA was isolated from livers of male pups
that are developmentally exposed to DMSO and BPA and mRNA levels were
quantified by quantitative PCR.

Data was normalized to 18S rRNA and

presented as a mean arbitary units + S.E.M. (n=9-10 mice per group). An
asterisk (*) represents a statistical difference between pups from control to
pups from BPA exposed dams (p≤0.05).
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Table 1. Detailed sequences for list of primers used in qPCR for
quantifying gene expression
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ABSTRACT
Bisphenol A (BPA) is an endocrine disruptor available ubiquitously in
environment. BPA is exposed to humans through several forms such plastic
bottles, canned food and even through dental sealants.

BPA is rapidly

metabolized and excreted from body either through urine or feces.

BPA

glucuronide (BPA-Gluc) is a major metabolite whereas BPA sulfate (BPA-S) is
minor metabolite formed.

As BPA metabolites are termed non-toxic

compounds, BPA metabolism has an important role in BPA induced toxicity.
Studies have identified in humans, correlation between urinary BPA levels and
occurrence of metabolic syndrome components such as obesity, diabetes and
cardiovascular diseases. Obesity is a hallmark of metabolic syndrome, which
is a complex condition involving accumulation of fat mass and changes in
several gene expression. Both in humans and rodents, altered metabolism
and disposition of xenobiotics were observed with obesity and other metabolic
syndrome conditions. BPA disposition during metabolic syndrome conditions
such as obesity, fatty liver and diabetes is very less known. In this study we
administered BPA (10 mg/kg, i.v.) in lean and obese rats. Bile, blood and
urine samples were collected at different time interval and analyzed using
UPLC-MS/MS.

Along with in vivo BPA disposition studies hepatic

glucuronidation and sulfation enzymatic assays were performed to identify
whether obesity altered hepatic metabolic processes.

Our results indicate

obese rats have decreased hepatic glucuronidation and increased hepatic
sulfation. Changes in hepatic phase II and III protein expression in obese rats
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resulted in altered BPA metabolism and disposition.

In obese rats BPA

metabolites specifically BPA-Gluc levels were increased in urine and
decreased in bile compared to lean rats. These altered BPA metabolism and
disposition during obesity suggests in humans, in depth evaluation of urinary
BPA levels such as ratio of metabolite to parent compound are needed to
correlate BPA exposure to occurrence of obesity.
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INTRODUCTION
BPA is a bi-product of plastic manufacturing, available ubiquitously in
environment and exposed to humans through several forms (Vandenberg et
al., 2009).

According National Health and Nutrition Examination Survey

(NHANES) 92.6% of people analyzed have BPA in their urine (Calafat et al.,
2008). Rodent studies documented, BPA can cause several adverse effects
such as obesity, insulin resistance, oxidative stress, endocrine disruptors and
behavioral changes (Somm et al., 2009; Vandenberg et al., 2009; Jasarevic et
al., 2011). BPA is highly metabolized in liver and eliminated by urinary and
fecal excretion (Pottenger et al., 2000; Volkel et al., 2002). BPA-glucuronide
(BPA-Gluc) and BPA-sulfate (BPA-S) are the major metabolites formed in
humans and mice The UGT2B family and SULT enzymes are major
biotransformation enzymes involved in BPA conjugation (Nishiyama et al.,
2002; Hanioka et al., 2008). In rodents, Abcc2 is the predominant transporter,
which mediates BPA-Gluc excretion from liver into bile (Inoue et al., 2005).
Obesity is a hallmark disease of metabolic syndrome and widely considered
as a complex condition. Obesity is characterized by body mass index (BMI>
30 kg/m2). There is growing concerns of obesity affecting people worldwide
and approximately above 30% of US population was effected by obesity of
which 5% are considered as morbidly obese (Ogden et al., 2006; Flegal et al.,
2010). The CDC estimates that more than 86% of US adults will be overweight
and more than 50% obese by the year 2030 (Wang et al., 2008). One of the
major complications during obesity is NAFLD, 15-39% of US population are
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effected by NAFLD (Younossi et al., 2002; Collantes et al., 2004). Obese
people have altered drug absorption, distribution, metabolism and elimination
process. Several studies documented altered metabolism and drug disposition
in both obesity and NAFLD disease conditions (Naik et al., 2013). During
obesity altered pharmacokinetic parameter are related to several factors such
as change volume of distribution, fat mass and clearance (Brill et al., 2012).
Apart from these factors hepatic metabolism, which includes phase I, II and III
(drug transporter) proteins also plays important role in pharmacokinetics
aspects in obese population (Brill et al., 2012). Both in humans and rodents,
altered phase I and, II enzymes and drug transporter expression were
observed during NAFLD (Naik et al., 2013). Moreover, during obesity and
non-alcoholic fatty liver disease (NAFLD) conditions phase II enzymes and
drug transporters involved in BPA metabolism are altered (More and Slitt,
2011; Hardwick et al., 2013).
There is very less known about whether changes in hepatic metabolic
pathways in obese population alters endocrine disruptors disposition. In this
study we want to determine how obese population handle BPA body burden.
In this study we also want to determine whether changes in phase II enzymes
and drug transporters during metabolic syndrome conditions alter BPA
metabolism and disposition. We used lean and obese zucker rat and injected
BPA to identify how obese population handle high amount of BPA exposure.
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Materials and Methods:
Animals: Nine-week old lean and obese zucker rats (n=6) were purchased
from Charles River Laboratories International, Inc. (MA, USA).

Rats were

housed under a constant dark/light cycle (12 h/12 h), and given food and
water ad libitum for 2 weeks at Department of Biomedical and Pharmaceutical
Sciences vivarium. Rats used for this study are 11-week old. All the animal
experiments were conducted at the University of Rhode Island using
procedures approved by the Institutional Care and Use Committee (IACUC).
Surgical procedure: Both lean and obese zucker rats were anaesthetized
using urethane (1.5 mg/kg, ip). Left femoral vein and artery were cannulated
using PE-50 polyethylene tubing and bile duct was cannulated using PE-10
polyethylene tubing. Before injection of BPA femoral artery and vein cannula
are flushed with saline. BPA (10 mg/kg, i.v.) (Moors et al., 2006) dissolved in
polyethylene glycol 400 and isotonic saline (20:80, w/w) was injected through
femoral vein.

~200 µL of blood was collected from femoral artery into

heparanized tubes at 0, 2, 10, 20, and 40 min time interval after injection of
BPA. Equal amount of saline was injected through femoral vein after every
blood collection. Bile samples were collected at 0, 15, 30, 45 and 60 min time
intervals after BPA administration. At the end of 90 min, urine was collected
using 3 mL syringe and 22-gauge needle by puncturing bladder (Lickteig et al.,
2007). At the end rats were euthanized and liver were collected and snap
frozen in liquid nitrogen.

All samples collected were stored in -80°C until

analysis.
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Microsomes preparation:

200mg of liver tissue (n=3-6 per group) was

washed with ice-cold saline and 50mM sodium pyrophosphate buffer (pH-7.4).
Following washing livers were homogenized in 600 ml homogenizing buffer
(0.25M Sucrose, 50mM Tris-Hcl (pH-7.8), 0.5mM EDTA, 20mM BHT, 0.1mM
DTT) and centrifuged at 10,000x g for 15 min. Supernates were centrifuged
again at 100,000x g for 60 min. Cytosolic supernate was transferred to tube
and stored at -80°C for future use. Microsomal pellet was re-suspended in resuspending buffer (0.25M Sucrose, 10mM Tris-Hcl (pH-7.8), 1mM EDTA,
20mM BHT and 20% glycerol) and stored at -80°C for future use.
Enzymatic Glucuronidation and analysis:

Hepatic microsomal fractions

(0.0075 mg) were incubated with 1µM BPA and 2mM UDPGA in 50mM
phosphate buffer (pH-7.0) for 30 min at 37°C. At the end of Incubation, tubes
were heated in boiling water to deactivate protein and centrifuged at 14000Xg
for 10 min. Supernatant were collected and 50 µL of each sample injected in
to HPLC-UV (System Gold®, Beckman Coulter, Inc.).

BPA and BPA-Gluc

were analyzed with a gradient elution, 80% ACN and 20% 20mM phosphate
Buffer (pH-2.7) at 1 mL/min flow rate using ZORBAX SB-Aq column (5µm,
4.6X150mm, Agilent Technologies) (Wen et al., 2013). BPA and BPA-Gluc
were identified using standards of BPA (sigma-aldrich) and BPA-Gluc (Toronto
research chemicals, Canada) made in 50 mM phosphate buffer (pH-7.0). BPAGluc and BPA are eluted at 7.4 and 10 minutes respectively. BPA and BPAGluc were quantified by comparing area of peak with standards.
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Enzymatic Sulfation and analysis: The cytosolic fraction were incubated
with 2.4 µM of radiolabeled sulfonyl donor [35S]-3'-phosphoadenosine-5'phosphosulfate (35S-PAPS) and 4 µM BPA in 20 mM potassium phosphate
(pH-7.0). The reaction mixture was incubated for a 60 min at 37ºC, after
incubation protein reaction was stopped by heating in boiling water for 30 sec,
and centrifuged at 14,000 x g for 20 min to pellet the protein. For separation
of reaction components, the resulting supernate was injected onto
phenomenex synergi polar-RP column (50 x 2.00 mm, 4 micron). A linear
gradient of 15-80% acetonitrile and 20 mM potassium phosphate (pH-2.7) in 8
min was used as mobile phase to separate excess
35

35

S-PAPS from BPA-35S.

S-labeled peaks were quantified on a flow scintillation analyzer (Packard

Bioscience, 500 TR series) with Perkin-Elmer Ultima Flo-M scintillation
cocktail.

35

S-PAPS was eluted with the solvent front and BPA-35S at 4.8 min.

Sample preparation and detection: BPA and BPA metabolites were
detected using sold phase extraction followed by UPLC-MS/MS. Method used
in this study is a modified version of previously published study by Coughlin et
al., 2011. Brefily, 100 µL of plasma, bile and urine samples were diluted to 1
mL with dilution buffer (Citrate, 100 µL of 250 mM ammoniumacetate (pH 5),
80 µL of 1 M formic acid, and water) and extracted using Bond Elut Plexa
cartridges (Varian Inc., Palo Alto, CA, USA; 60 mg, 1 mL).

BPA and its

metabolites are eluted in 8mL of elution solution (ethanol, methanol and
acetonitrile). Eluted solution is evaporated and extract was reconstituted in
200 µL 75% acetonitrile in water. 10 µL of reconstituted sample was injected
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into UPLC MS/MS, BPA and its metabolites were quantified by comparing
standards (Coughlin et al., 2011). In this study data represented from bile and
urine sample have n= 6 samples per group whereas plasma samples are n=
5-6 per group.
Statistical Analysis: The statistical significance between groups was
determined using one-tailed student t-test. Data are presented as mean ± SE,
with P ≤0.05 considered statistically significant.
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Results:
Enzymatic BPA glucuronidation and Sulfation: Figure 1 illustrates hepatic
glucuronidation and sulfation in both lean and obese rats.

Hepatic

glucuronidtation was significantly reduced in obese rats compared to leans by
42% (Figure 1A). In Vitro sulfation assay showed 1.4-fold increase in hepatic
sulfation in obese zucker rats compared to lean zucker rats (Figure 1B).
Effect of obesity on BPA and its metabolite disposition:

Cumulative

biliary excretion of BPA and its metabolites are shown in figure 2. Obese
zucker rats have increased biliary excretion of BPA compared to leans (figure
2A). In obese rats, 21.82 µg/mL of cumulative amount of BPA excreted into
bile whereas lean rats have 7.85 µg/mL indicating 3-fold increase of BPA in
bile. BPA levels in bile are significantly higher at all time points in obese
zucker rats compared to lean rats.

BPA-Gluc is a major metabolite

quantitatively excreted into bile. In obese zucker rats BPA-Gluc excretion into
bile was significantly decreased compared to lean rats. Significant differences
in BPA-Gluc levels in bile was observed at initial time points such as 15, 30
and 45 min. These significant differences in BPA-Gluc levels were diminished
at later time pioints.

Biliary excretion of BPA-S was decreased in obese

compared to lean rats (figure 2C). Decrease in BPA-S biliary levels in obese
rats was observed at all time points.
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Figure 3 shows cumulative levels of BPA and its metabolites in plasma.
Cumulative plasma BPA levels did not altered in obese rats compared to lean
rats. Cumulative BPA-Gluc levels in plasma showed an increasing trend in
obese compared to lean rats (figure 3B). Cumulative BPA-S levels in plasma
were unaltered in obese rats (figure 3C). Figure 4 shows cumulative levels of
BPA and its metabolites in urine. Interestingly, although no significant changes
were observed with plasma BPA-Gluc and BPA-S levels urine BPA-Gluc and
BPA-S levels increased significantly.
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Discussion:
Etiology of obesity and metabolic syndrome includes several factors like diet,
decreased physical activity, genetics and environmental chemicals (Heindel
and vom Saal, 2009).

Rodent studies identified several environmental

chemical and drug molecules that can cause obesity and NAFLD (Heindel and
vom Saal, 2009). Environmental chemicals that cause obesity are termed as
obesogens (Heindel and vom Saal, 2009). Several studies have correlated
urinary BPA levels in humans with altered kidney function and several
condition of metabolic syndrome such as diabetes, cardiovascular and obesity
(Lang et al., 2008; Melzer et al., 2010; Trasande et al., 2012; Trasande et al.,
2013). Rodent studies identified both developmental and daily BPA exposure
causes obesity and hepatic steatosis, a benign condition of NAFLD (Somm et
al., 2009; Marmugi et al., 2012). As BPA exposure and occurrence of obesity
are interlinked to each other, in this study we showed how changes in phase II
and drug transporter expression during obesity alters BPA body burden.
Obese zucker rats have spontaneous mutation in fa gene (leptin receptor)
present in chromosome 13 (Kanasaki and Koya, 2011). Obese zucker rats
displayed hyperglycemia, hypelipidemia and hyperinsulinemia conditions and
these rats are used as a rodent models for obesity, diabetes and NAFLD
disease conditions (Kanasaki and Koya, 2011).

As mentioned previously

obesity and NAFLD disease condition have altered pharmacokinetics of drug
substances in both human and rodents.

Similar to obese patients, obese

zucker rats displayed altered acetaminophen disposition and have decrease in
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acetaminophen-induced toxicity (Blouin et al., 1987; Lickteig et al., 2007;
Hardwick et al., 2013). Obese Zucker rats also displayed altered phase II
enzyme and drug transporters expression.

In this study we used obese

zucker rats as a model to identify whether change in metabolism gene
expression during obesity alters BPA disposition.
BPA majorly undergo extensive metabolism BPA-Gluc is a major metabolite
formed whereas BPA-S is minor metabolite. In both humans and rodents BPA
is metabolized extensively in liver and intestines (Pottenger et al., 2000; Volkel
et al., 2002).

In rodents, Ugt2b1 is a liver specific enzyme, which is

predominantly involved in hepatic glucuronidation of BPA (Yokota et al.,
1999). Studies have documented hepatic Ugt2b1 expression decreased in
obese zucker compared to lean (Kim et al., 2004). Decrease in observed
hepatic glucuronidation capacity in obese zucker rats is due to decrease in
Ugt2b1 expression. In humans, BPA is metabolized by several UGT isoforms
such as 2B15, 2B7, 1A8 and 1A9 (Hanioka et al., 2008).

Among these

isoforms UGT2B15 was considered to be major isoform involved in hepatic
BPA glucuronidation (Hanioka et al., 2008).

Interestingly in humans UGT

isoforms expression involved in BPA metabolism were not altered with
development of NAFLD, indicating BPA glucurondation may not be altered
during obesity and NAFLD (Hardwick et al., 2013).

Studies identified

expression of certain UGT isoforms may not translate to their activity (Court,
2010).

Lorazepam, and oxazepam, substrates for UGT2B15 were

metabolized more in obese patients (Abernethy et al., 1983) whereas UGT2B7
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substrate mycophenolic acid conjugation was decreased during diabetes
(Dostalek et al., 2011). These changes indicate altered metabolism especially
hepatic BPA glucuronidation during obesity, diabetes and NAFLD, which are
components of metabolic syndrome.
Both in humans and rodents BPA sulfation is a minor pathway, which is
catalyzed by SULT1A1 predominantly (Nishiyama et al., 2002). In rodents,
diet induced obesity increased Sult1a1 expression, which is similar to
SULT1A1 expression in human steatotic livers (Hardwick et al., 2013).
SULT1A1 is involved in sulfation of phenolic compounds like acetaminophen.
Studies have documented during NAFLD both in human and rodents
acetaminophen sulfation increased (Lickteig et al., 2007; Hardwick et al.,
2013). This indicates both humans and rodents have increased BPA sulfate
formation during obesity.
In humans BPA is rapidly metabolized and excreted through urine whereas, in
rodents BPA metabolites are excreted through feces (Volkel et al., 2002).
Transporters involved in BPA metabolites excretion are different in human and
in rodents (Mazur et al., 2012). BPA-Gluc, a major metabolite formed in BPA
metabolism is transported by Abcc2 in rodents (Inoue et al., 2005).
Transporter assays using membrane ATPase assays identified in humans
ABCC3 might be involved in BPA-Gluc transport (Mazur et al., 2012). ABCC3
is efflux drug transporter present on basolateral membrane of hepatocyte and
inovolved in excretion of endogenous and xenobiotics from liver into blood
(Klaassen and Aleksunes, 2010). In obese zucker rats hepatic Abcc2
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expression was significantly downregulated (Geier et al., 2005). Decrease in
hepatic phase II and III (drug transporter) expression in obese rats play major
role in altered disposition of BPA. Decrease cumulative BPA-Gluc levels in
bile is may be due to decreased Abcc2 expression. Studies have documented
that rats lacking Abcc2 show decreased BPA-Gluc biliary excretion (Inoue et
al., 2005).

Decreased biliary BPA-Gluc excretion resulted in increase of

plasma and urine cumulative BPA-Gluc levels.
Changes in humans, during NAFLD hepatic altered phase II and III protein
expression was observed (Hardwick et al., 2011; More and Slitt, 2011;
Hardwick et al., 2013). As mentioned previously, in humans during obesity
increased glucuronide conjugate formation of lorazepam, and oxazepam was
observed, which are substrates for UGT2B15 (Abernethy et al., 1983).
Increase in UGT2B15 activity in obese people indicates that obese patient can
detoxify BPA more efficiently than normal population. Moreover in humans,
hepatic ABCC3 expression increased with increase in progression of NAFLD
(Hardwick et al., 2011; More and Slitt, 2011). This indicates obese people will
have high clearance of BPA-Gluc from liver, which ultimately results in
increased BPA-Gluc urinary excretion.
As mentioned previously, in humans urinary BPA levels are correlated with
obesity. In most of these studies only total urinary BPA levels were observed
and these studies did not specified ratio of BPA and its metabolites in human
urine samples (Carwile and Michels, 2011; Trasande et al., 2012; Wang et al.,
2012). May be high amount of total BPA in obese human urine may be result
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of altered metabolism and disposition of BPA. Correlation between obesity
and urinary BPA levels observed from previous studies may need more
evaluation. Detailed evaluation of BPA and its metabolites in human urine
gives more information whether obesity and BPA exposure are interlinked in
humans or not.
In conclusion, hepatic clearance plays a major role in detoxifying and
elimination of BPA from body. We think changes in phase II and III protein
during obesity will alter hepatic clearance of BPA and its metabolites. Our
model of obesity in which altered hepatic phase II and III protein expression
resulted in altered BPA metabolism and disposition. Although our model did
not show same changes that are observed in obese human population, it
strongly indicates that BPA metabolism and disposition will be altered during
obesity. In humans, correlation between total BPA levels in urine cannot be
correlated to obesity, as obese population is known to have altered ADME. In
depth evaluation of BPA levels such as ratio of metabolite to parent compound
are needed to correlate BPA exposure to occurrence of obesity.
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Figure Legends:
Figure 1. Altered hepatic BPA glucuronidation and sulfation due to
obesity. A) BPA hepatic glucuronidation was decreased in obese zucker rats.
Hepatic microsomes are incubated with 1 µM of BPA and 1mM of UDPGA for
30 min at 37°C. Amount of BPA-Gluc formed was measured using HPLC-UV
and data represented as average BPA-Gluc formed (nmol/min/mg) ± S.E.M
(n=6 per group). B) BPA hepatic sulfation was increased in obese zucker rats.
Hepatic cytosolic fractions were incubated with 4 µM BPA and 2.4 µM

35

S-

PAPS for 1 hour at 37 °C. Amount of BPA-35S formed was analyzed using
HPLC attached to scintillation counter detector and data represented as
average BPA-35S formed (pmol/min/mg) ± S.E.M (n=6 per group). Asterisk (*)
represents statistical significance between lean and obese zucker rats
(p<0.05).
Figure 2. Altered hepatic BPA and BPA metabolites disposition in bile
due to obesity. Cumulative biliary excretion of BPA (A), BPA-Gluc (B) and
BPA-S (C) in both lean and obese zucker rats following BPA administration.
Both lean and obese zucker femoral artery and, vein, and bile duct were
cannulated.

BPA (10mg/kg) administered through femoral vein and bile

samples were collected at 15, 30, 45, 60 and 90 min time intervals. BPA and
BPA metabolites were analyzed using UPLC-MS/MS technique. Asterisk (*)
represents statistical significance between lean and obese zucker rats
(p<0.05).

	
  

146

Figure 3. Altered hepatic BPA and BPA metabolites disposition in
plasma due to obesity. Cumulative plasma levels of BPA (A), BPA-Gluc (B)
and BPA-S (C) in both lean and obese zucker rats following BPA
administration. Both lean and obese zucker femoral artery and, vein, and bile
duct were cannulated. BPA (10mg/kg) administered through femoral vein and
blood samples were collected at 2, 10, 20, 40 and 60 min time intervals. BPA
and BPA metabolites were analyzed using UPLC-MS/MS technique. Asterisk
(*) represents statistical significance between lean and obese zucker rats
(p<0.05).
Figure 4. Altered hepatic BPA and BPA metabolites disposition in urine
due to obesity. Cumulative urinary excretion of BPA (A), BPA-Gluc (B) and
BPA-S (C) in both lean and obese zucker rats following BPA administration.
Both lean and obese zucker femoral artery and, vein, and bile duct were
cannulated.

BPA (10mg/kg) administered through femoral vein and urine

samples were collected at 30, 60 and 90 min time intervals. BPA and BPA
metabolites were analyzed using UPLC-MS/MS technique. Data represented
as averageof BPA or its metabolites (ng/mL) ± S.E.M (n=6 per group).
Asterisk (*) represents statistical significance between lean and obese zucker
rats (p<0.05).
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Conclusion
In conclusion, we observed Abc drug transporter expression was altered with
obesity, age and maternal diet.

Changes in Abc drug transporters can alter

hepatic clearance and endocrine disruptor disposition. Abc drug transporters
expression was not only regulated by transcription factors but also with
epigenetic mechanisms and serum metabolism-related hormones, which are
involved with glucose and lipid metabolism. Detailed conclusions for each study
are below:
In first study we observed ontogeny of drug transporters and physiological factors
during development of obesity are sex specific. Sex-specific correlations were
observed between physiological factors and gene expression.

Sex-specific

differences in correlations and expression of genes are may be due to regulation
of hepatic drug transporters with endocrine hormones such as androgens,
estrogen and growth hormones, which are known to be different in both male and
females. Correlations between gene expression and physiological factors
indicate serum hormone may have a role in regulation in drug transporters during
development of obesity.

In males, high correlations with serum resistin and

glucagon with hepatic Abc transporter expression indicates serum resistin and
glucagon can be a possible biomarker for change in Abc drug transporter
expression during development of obesity.
Second study illustrated that maternal diet can regulate hepatic gene expression.
In male pups, BPA developmental exposure decreased key hepatic Abc drug
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transporters, which are involved in efflux of xenobiotics and endogenous
hormone conjugates from liver. Observed developmental BPA exposure effects
are similar to estrogen developmental exposure effects.

BPA and estradiol

development exposure also decreased transcription expression and activity,
which were involved in regulation of Abc expression in liver. Phytoestrogen such
as genistein supplementation in maternal diet along with developmental BPA
exposure reversed changes observed with BPA exposure. Global decrease in
hepatic Abc drug transporters, Phase II enzyme and transcription factor
expression and activity caused by BPA and estradiol involves epigenetic effects.
Both

BPA

and

estradiol

developmental

exposures

increased

histone

deacetylases (Hdacs) expression whereas genistein co-administration decreased
Hdacs, which are involved in down regulation of gene expression by epigenetic
mechanisms.
In third study we observed altered dispositon of BPA during obesity. Changes in
hepatic Phase II enzymes and Abc drug transpoters are reflected in changes in
BPA

disposition.

Specifically,

decrease

in

hepatic

UDP-glucuronosyl

transferases 2b1 (Ugt2b1) in obese Zucker rats resulted in decrease in BPA
glucuronidation in obese rats.

Decrease in BPA glucuronidation, which is a

major pathway for detoxification of BPA, increases body burden of BPA in obese
rats. Decrease in hepatic Abcc2 expression obese rats resulted decrease in
BPA-glucuronide (BPA-gluc) levels in bile which eventually resulted in increase
of BPA-gluc levels in plasma and urine. Increase of hepatic sulfonation in obese
rats caused increase in BPA-S levels in urine, although BPA-S decreased in bile.
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These results supports that altered Phase II and Abc drug transporter expression
in liver during obesity will results in altered disposition of endocrine disruptors
and increases body burden of BPA.
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